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ABSTRACT 
Introduction:  Lymphomas are the most frequent non-epithelial oral and maxillofacial 
malignancy.  Non-Hodgkin lymphoma (NHL), though not common in the oral cavity is 
reported with increasing frequency in patients with human immunodeficiency virus (HIV) 
and acquired immune deficiency syndrome (AIDS).  An increased risk of lymphoma 
development is also seen in persons with primary immunodeficiency and connective tissue 
diseases and patients on cytotoxic immunosuppressive treatment.  With South Africa 
looming as a country with the highest incidence of HIV and AIDS worldwide, an 
epidemiologic study would provide valuable insight into head and neck lymphomas in a 
defined South African population. 
Aim:  This retrospective review is aimed at evaluating the frequency and clinico-pathologic 
characteristics of patients diagnosed with head and neck lymphoma at the Department of 
Oral Pathology, University of the Witwatersrand, Johannesburg over the 20 year period, 
1993-2012. 
Methods:  Histopathology reports of patients diagnosed with lymphomas of the head and 
neck were reviewed.  Epidemiological data including the demographic, clinical, laboratory, 
and histological parameters for each patient were recorded.  Variables included, amongst 
others age, gender, site, size of tumour, histologic subtype of lymphoma and year of 
diagnosis.  Lymphomas were classified according to the 2008 World Health Organisation 
classification of tumours of lymphoid neoplasms. 
Results:  There were 504 patients (2.24%) with head and neck lymphomas.  The median 
age was 39 years and the age range was 2 to 100 years.  The male:female ratio was 1.13:1.  
The cervical lymph node was the most common anatomic site (115 cases) and the maxilla 
(60 cases) was the most common extranodal site.  Plasmablastic lymphoma (159 cases) 
was the most common histologic subtype followed by diffuse large B-cell lymphoma   
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(155 cases).  The most common Hodgkin’s lymphoma (HL) was nodular sclerosing HL (21 
cases).  Ninety percent of cases were NHLs and ten percent were HL.  Seventy-three 
percent of cases were extranodal and twenty-seven percent were nodal in origin.  A 
mass/swelling was found to be the most common clinical feature and B symptoms only 
occurred in one patient. 
Conclusion: This study confirmed the increase in head and neck lymphoma frequency over 
the 20 year period, contrary to that found in Western countries, which show a decline in 
incidence with highly active antiretroviral therapy.  Oral and maxillofacial lymphomas 
occurred predominantly in the third decade with a strong male bias.  Most were extranodal, 
presenting as ulcerated painful swellings.  This study serves as a baseline for future head 
and neck lymphoma studies, especially in a South African setting.   
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CHAPTER 1 
 
1.0  INTRODUCTION 
 
Lymphomas comprise a diverse group of neoplasms, affecting the lympho-reticular 
system, originating from cells of the immune system at different stages of their 
differentiation and eventually resulting in varying histology, immunophenotypes, genetic 
abnormalities and clinical findings (Agrawal, Agrawal & Kambalimath 2011; Zini et al. 
2012).  Non-Hodgkin’s lymphomas (NHLs) can arise from either B cells, T cells or NK 
cells, but arise more frequently from B cells (Cawson & Odell 2002), and plasmacytoma is 
a special clinical entity that occurs primarily in the bone marrow (Scherfler et al. 2012).  
However, despite their cell type, all lymphomas are malignant and can range from being 
relatively indolent to highly aggressive in nature (Cawson & Odell 2002; Zini et al. 2012).  
All lymphoid neoplasms are referred to as monoclonal as they are derived from a single 
transformed cell (Kumar, Abbas & Aster 2007). 
 
Over the last decade, great progress has been made in formulating an internationally 
recognised classification for lymphoid neoplasms.  The widely accepted World Health 
Organisation (WHO) classification of haemato-lymphoid neoplasms includes the 
morphologic, phenotypic, genotypic and clinical features of each entity.  This classification 
separates lymphoid neoplasms into Hodgkin’s lymphoma (HL), NHL and lymphoid 
leukaemia and thereby encompassing the solid and circulating phases of lymphoma and 
lymphoid leukaemia (Huh 2012).  As traditionally known and for simplification purposes, 
lymphomas are referred to as HL and NHL (Kumar, Abbas & Aster 2007). 
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 A number of NHL histotypes do not originate from lymph nodes and arise from sites that 
do not normally contain lymphoid tissue (Bussu et al. 2013).  These are referred to as 
primary extranodal lymphomas (Bussu et al. 2013).  According to Kemp et al. (2008), up 
to 40% of NHLs occur at extranodal sites and about 2-3% of these extranodal lymphomas 
occur in oral sites. 
 
Lymphomas were thought to be exceptionally uncommon in the mouth but to frequently 
affect the cervical lymph nodes (Cawson & Odell 2002).  However, with the acquired 
immune deficiency syndrome (AIDS) pandemic over the last few years, lymphomas may 
now account for almost 2% of oral neoplasms (Cawson & Odell 2002).  Apart from human 
immunodeficiency virus (HIV) and AIDS, an increased risk of developing a lymphoma is 
also seen in persons with primary immunodeficiency diseases, those with connective tissue 
diseases, especially rheumatoid arthritis and Sjögren’s syndrome, and patients on cytotoxic 
immunosuppressive treatment (Cawson & Odell 2002).  
 
Lymphomas are the most frequent non-epithelial malignant tumours in the oral and 
maxillofacial region and they can present as nodal disease, extranodal or a combination of 
both (Zini et al. 2012).  Following the gastrointestinal tract, the head and neck region is 
said to be the second most frequent site for extranodal lymphomas (Bussu et al. 2013; 
Agrawal, Agrawal & Kambalimath 2011).  HL is known to present as nodal disease 
whereas NHL may develop extranodally (Agrawal, Agrawal & Kambalimath 2011).  HL 
and NHL each display distinct morphological characteristics, biological behaviour, 
epidemiological and prognostic features, with varying responses to treatment (Oluwasola 
et al. 2011). 
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HL is characterised by the presence of distinct Reed-Sternberg giant cells, a feature that 
sets HL apart from NHL, and which in involved nodes are generally greatly outnumbered 
by non-neoplastic inflammatory cells (Kumar, Abbas & Aster 2007).  HL has a fairly good 
prognosis.  NHL in itself is a diverse group of lymphoid malignancies and is 
approximately nine times more common than HLs (Walter et al. 2015).  Due to the great 
diversity of NHL, its prognosis and treatment varies.  Treatment involves radiation and/or 
chemotherapy and depending on the cell type, a specific chemotherapy regime must be 
followed (Wilson & Wright 1986). 
 
NHL is not commonly seen in the oral cavity but has been reported with some frequency in 
patients with AIDS (Basavaraj et al. 2012).  Some studies state that malignant lymphomas 
are the second most frequent malignancy of the oral cavity and maxillofacial region 
following squamous cell carcinoma (Kemp et al. 2008; Scherfler et al. 2012) while others 
say it ranks third following squamous cell carcinoma and salivary gland neoplasms 
(Triantafillidou et al. 2012; Kolokotronis et al. 2005).  Some of the other sites affected in 
the head and neck region include Waldeyer’s tonsillar ring (WR), the orbit(s), paranasal 
sinuses, nasal cavity, salivary glands and larynx. 
 
Lymphomas make up approximately 10-12% of all malignancies in paediatric patients 
(Gualco et al. 2010).  Of this, approximately 4-7% is HLs and 7-10% is NHLs (Gualco et 
al. 2010).  Childhood NHL differs from adult NHL in biological behaviour, staging 
system, disease types, treatment and outcome (Gualco et al. 2010).  NHLs in adults are 
often low to intermediate grade, whereas the majority of NHLs in children are high grade 
(Gualco et al. 2010).  Over the past two decades, the incidence of NHL among children 
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younger than 15 years, has remained almost constant, while there has been a slight increase 
in incidence for the age group 15-18 year olds (Gualco et al. 2010). 
 
Whilst there have been various global epidemiological reports on head and neck 
lymphomas, each focusing on different epidemiologic variables including amongst others 
age, gender, anatomic site (Bussu et al. 2013; Iguchi et al. 2012), there is a dearth in the 
literature regarding African and more especially South African studies on head and neck 
lymphomas. 
 
Furthermore, numerous reports in the literature reflect on the increase in head and neck 
lymphomas with the HIV and AIDS pandemic (Chetty, Sudi & Abayomi 2012; Agrawal, 
Agrawal & Kambalimath 2011; Brower 2011), and with South Africa looming as a country 
with the highest incidence of HIV and AIDS (Granich et al. 2015) worldwide, a study of 
this nature would provide valuable and novel insight on the epidemiology of head and neck 
lymphomas within a South African population.  Due to the change in disease incidence, 
patterns and virulence over the past two decades, a retrospective study of this nature will 
help us evaluate how Africa and South Africa compare to the rest of the world in terms of 
disease. 
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CHAPTER 2 
 
2.0  LITERATURE REVIEW 
 
2.1 Terminology: Head and neck lymphomas 
Terminology pertaining to lymphomas encountered in the oral and maxillofacial region 
varied considerably in the literature, with studies using terms ranging from head and neck 
lymphomas to cranio-maxillofacial lymphomas (Bussu et al. 2013; Scherfler et al. 2012).  
Similar to our study, most international studies on head and neck lymphomas generally 
encompassed all lymphomas of the head and neck region encountered in the oral and 
maxillofacial pathology diagnostic unit (Hart et al. 2004; Scherfler et al. 2012; 
Triantafillidou et al. 2012).  Although this study was performed in an oral pathology unit, 
where the referral cases are mostly oral, perioral and orofacial as well as salivary gland 
neoplasms, the odd cases of lymphomas of the larynx, orbit and scalp diagnosed within the 
unit were included in the study as part of the head and neck group of lymphomas.   
 
Kolokotronis et al. (2005) in their study, excluded jaw NHLs as they felt it should be 
discussed with lymphomas of the bone.  However, the only study with specific inclusion 
and exclusion criteria was the South African study by Chetty, Sudi & Abayomi (2012) that 
excluded central nervous system (CNS), thyroid, laryngeal, nasal and paranasal lesions as 
well as the so-called ‘grey-zone’ lymphomas and precursor lymphoid neoplasms.  Their 
inclusion criteria included the oral cavity (all areas from the lips anteriorly and extending 
posteriorly up to, but excluding the oropharynx).  Jaw lesions were included and skin 
lesions of the head and neck were included as primary cutaneous lesions. 
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2.2 Epidemiology 
2.2.1 Lymphoma incidence in the West and Asia 
According to Huh (2012) the lack of a standardised classification system, has had a great 
negative impact on the epidemiological study of malignant lymphomas worldwide and has 
therefore prevented important global comparison and analysis.  However, the general 
consensus with the information at hand is that malignant lymphomas are more common in 
the developed countries (Europe, North America, Australia and New Zealand) and less 
common in the developing countries (Asia and Africa), with the exception of Burkitt 
lymphoma (BL) in its endemic population (Huh 2012).  East Asia has one of the lowest 
incidence rates (Huh 2012).  Globally, the incidence of malignant lymphoma has shown to 
increase by 3-4% over the past four decades, however during recent years, some 
stabilisation has been noticed in the developed countries (Huh 2012). 
 
The NHL incidence has been on the increase since 1970 in all populations (Huh 2012).  
However, in the West especially the United States of America (USA), the steady increase 
of 3-4% each year started to show a slight decrease to 1-2% by the mid 1990 (Huh 2012).  
While in Asia (Korea) a consistent increase was seen with no stabilisation (Huh 2012). 
 
In comparison to NHL, HL has a consistently lower incidence rate globally, which is either 
decreasing or static (Huh 2012).  The reason for this however is not known (Huh 2012).  
On the other hand, an increase in the HL incidence has been observed in the female 
population (Huh 2012).  This increase in HL in the Korean female population has been 
attributed to females delaying motherhood and childbearing, linking this to being a means 
of protection against HL (Huh 2012).   
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Due to this new female trend, the HL incidence is expected to increase further (Huh 2012). 
It is also important to note the effects of environmental factors on lymphomagenesis.  This 
is highlighted by the difference in incidence in genetically similar ethnic populations 
(Koreans and Chinese) living in diverse environments, as illustrated by Huh (2012) in the 
example of resident Koreans versus migrant Koreans in the USA.  The risks of lymphoma 
development associated with a particular geographic area in a specific ethnic group would 
be dependent on the age at migration, duration of residence and residential neighbourhood 
(Huh 2012).  This was further illustrated by Clarke et al. (2011) as cited by Huh (2012) 
who found significantly higher rates of follicular lymphoma (FL), small lymphocytic 
lymphoma (SLL) and nodular sclerosing HL in Asians born in the USA when compared 
with foreign born Asians. 
 
Various international studies have been published on lymphomas of the head and neck 
(Bussu et al. 2013; Iguchi et al. 2012; Beasley 2012).  Previous reports show that 
lymphomas contributed about 5% of all head and neck malignancies (Iguchi et al. 2012; 
Scherfler et al. 2012).  However, a recent large scale USA database on head and neck 
cancers has shown lymphomas to have an incidence rate of 12.4% (Cooper et al. 2009 as 
cited by Iguchi et al. 2012).  Iguchi et al. (2012) showed a similar incidence rate of head 
and neck lymphomas of 15.1%.  This data is in keeping with the overall increase in the 
incidence of malignant lymphomas worldwide (Huh 2012).   
 
Over the past 30 years, the incidence of NHL has increased drastically in the USA as well 
as in other countries; however the USA has higher incidence rates compared to many other 
countries (Chiu & Weisenburger 2003).  The difference is evident especially for FL cases 
in Western countries compared to developing countries as well as in China and Japan 
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(Chiu & Weisenburger 2003).  The reason for these international differences has been 
attributed to geographic differences in aetiological and host factors. 
 
Generally however, the increase in the incidence of NHL is not well understood.  Possible 
reasons for this increase include improved diagnostic techniques, HIV and AIDS, 
immunosuppressive therapies, immunodeficiency, infections [Epstein-Barr virus (EBV), 
Human T-cell lymphotrophic virus (HTLV), Hepatitis C virus (HCV)], familial 
aggregation, blood transfusion, diet, agricultural and pesticide exposures, occupation, 
genetic susceptibility and lifestyle factors (Chiu & Weisenburger 2003). 
 
2.2.2 Lymphoma incidence in Africa 
According to Oluwasola et al. (2011), NHL is quite rare in most African countries; 
however there is a higher incidence in North and sub-Saharan Africa due to the high 
number of BL cases in kids in the tropical regions of Africa.  In 1976, Ibadan (Nigeria) 
reported one of the highest incidences of lymphoma cases globally, to the International 
Agency for Research on Cancer (Oluwasola et al. 2011).  However, the incidence of BL 
from the 1960s, 1970s and 1980s to 1990s has decreased from 50% to 37% and to 19.4% 
in the 1990s (Oluwasola et al. 2011).  This decrease was attributed to malaria control, 
better living conditions and possibly a decline in EBV infection (Oluwasola et al. 2011).   
 
A recent retrospective study in Ibadan from 1991-2005, also showed a decrease in the 
number of cases from 58 cases in 1991 to 24 cases in 2005 (Oluwasola et al. 2011).  The 
decrease was seen in both HL and NHL (Oluwasola et al. 2011).  The authors of this study 
do however err on the side of caution and in their study limitations mention possible 
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variables as to whether the study is a true reflection of the study population or not 
(Oluwasola et al. 2011). 
 
A study carried out by Ogwang et al. (2011) was aimed at assessing the accuracy of 
clinical and local pathology diagnosis of BL by using an outside pathology review 
diagnosis team.  This was in the hope of understanding the limitations in histopathology 
practice in a resource-constrained region (Uganda).  Uganda is endemic for BL and due to 
the high number of patient cases, diagnosis is frequently assumed during clinical 
consultation and during epidemiologic studies (Ogwang et al. 2011). 
 
Accurate histopathology diagnosis is critical for patient care and just as important for 
cancer registration and epidemiologic studies (Ogwang et al. 2011).  In Africa, less than 
50% of cancers are diagnosed using histopathology methods (Ogwang et al. 2011).  Due to 
the common presentation of BL in Africa, diagnosis is frequently clinically diagnosed and 
sometimes confirmed only by aspiration cytology (Ogwang et al. 2011). 
 
Some of the findings of this study included amongst other factors small biopsy size, 
inadequate tissue preservation and suboptimal tissue fixation creating challenges in 
accurate diagnosis by local pathologists (Ogwang et al. 2011).  Laboratory procedures are 
rarely supervised and there is a lack of written standardised operational procedures which 
forms a norm in developed countries (Ogwang et al. 2011).   
 
There is also a shortage of pathologists in Uganda and most pathologists in these resource-
constrained areas may not have been adequately trained and do not have the expertise in 
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NHL; more specifically in the histopathologic characteristics and anatomic presentation of 
BL (Ogwang et al. 2011). 
 
A study carried out in Malawi and Uganda which confirmed significant associations 
between HIV and BL was reanalysed by a review team who found no statistically 
significant association between HIV and BL (Ogwang et al. 2011).  This placed enormous 
doubt on the validity of the two studies (Ogwang et al. 2011). 
 
Similarly, a review committee did not find 100% diagnostic accuracy in previously 
diagnosed BL cases reported by Ogwang et al. (2011).  This study concluded that there is 
an urgent need to improve histopathological diagnosis in Africa prior to carrying out 
further more in depth clinical and epidemiologic studies (Ogwang et al. 2011). 
 
South African statistics are presumed to be more accurate, as South Africa is not as 
resource-constrained as some of the other African countries, and South Africa holds a 
worldwide reputation as a quality producer of internationally sought after medical 
specialists (Cassim & Ruggunan 2014).  Perhaps, an exception would be in rural areas 
where cancers may go undiagnosed due to poor access to adequate healthcare facilities, 
therefore compromising the accuracy of the statistics.  To the best of our knowledge no 
study has been done in South Africa to reanalyse or reassess previously reported studies. 
 
2.3 Aetiology 
2.3.1 Epstein-Barr virus (EBV) 
EBV infection is strongly associated with the adult population and it is said that about 90% 
of the people living in developed countries show evidence of previous EBV infection by 
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the time they are 40 years.  Immunocompromised patients, such as AIDS patients, are at 
increased risk of developing EBV associated primary brain lymphomas as well as other 
high grade B-cell NHLs.  Almost all endemic BL cases (Africa and New Guinea) have 
evidence of EBV; however, the sporadic cases (USA and other developing countries) show 
EBV in less than 20% of patients (Chiu & Weisenburger 2003).  EBV is seen in many 
lymphoma cases, for example extranodal NK/T-cell lymphoma (nasal type), however it is 
thought that most EBV infections are secondary infections as a result of reactivation of the 
latent virus in the immunocompromised patients (Chiu & Weisenburger 2003; Beasley 
2012).  EBV infection is thought not to have a great impact on the increasing NHL 
incidence (Chiu & Weisenburger 2003; De Roos et al 2013). 
 
2.3.2 Human T-cell lymphotrophic virus (HTLV) 
Cleghorn et al. (1995) (as cited by Chiu & Weisenburger 2003) stated that if patients are 
infected with human T-cell lymphotrophic virus-1 (HTLV-1), especially during the early 
childhood years, there is a great possibility of adult T-cell leukaemia/lymphoma 
developing.  The modes of transmission of this virus include blood transfusion, sexual 
contact and breastfeeding (Chiu & Weisenburger 2003).  Due to the rarity of this virus 
which leads to its rare T-cell subtype and its special geographic distribution (Japan, Central 
and South America, Africa, New Guinea and Caribbean Islands) it is thought that this is 
not the main cause leading to the rising NHL incidence (Chiu & Weisenburger 2003; 
Hennessy, Hanrahan & Daly 2004; Huh 2012). 
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2.3.3 Hepatitis C virus (HCV) 
According to some authors, there is an association between HCV and low grade B-cell 
NHLs in many cases.  However, epidemiologic studies have not found any conclusive link 
between these two entities and the recent HCV increase cannot explain the NHL pattern 
which began more than 30 years ago (Chiu & Weisenburger 2003). 
 
2.3.4 Immunodeficiency 
Congenital and acquired forms of immunodeficiency are said to be the biggest known 
contributing factor to increase the risk of NHL.  NHL is the most common malignancy in 
young individuals with the following conditions: Wiskott-Aldrich syndrome, ataxia 
telangiectasia, X-linked lymphroproliferative syndrome or combined immunodeficiency.  
EBV seems to be an important cofactor.  Congenital immunodeficiency conditions are rare 
and do not contribute much to the rising incidence of NHL (Chiu & Weisenburger 2003). 
 
Patients on immunosuppressive therapy following bone marrow or organ transplantation 
are 30-50 times at greater risk of developing NHL.  B-cell lymphomas have been seen to 
regress when the immunosuppressive drugs are stopped, however in some cases they can 
turn into aggressive NHLs.  Persistent EBV infection is what feeds this malignant process.  
However, EBV associated NHLs are rare and do not explain much of the NHL increase in 
general (Chiu & Weisenburger 2003).   
 
Malignant lymphoma affects 5% to 10% of HIV positive patients, and HIV infected 
individuals are more than 100 times at risk of developing NHLs compared to healthy 
individuals (Chiu & Weisenburger 2003; Folk et al 2006).  In fact, Ota et al (2014) 
reported the incidence of malignant lymphoma to be 60 to 200 fold greater in HIV infected 
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persons when compared to the general uninfected patient population.  HIV associated 
lymphomas are generally high grade neoplasms of B-cell lineage, mostly diffuse large B-
cell lymphoma (DLBCL), immunoblastic or Burkitt subtypes and often affect extranodal 
sites, such as the brain (Chiu & Weisenburger 2003; Folk et al 2006; Ota et al 2014). 
 
HIV associated NHL is due to inadequate immune surveillance of oncogenic herpes 
viruses such as EBV and human herpes virus 8 (HHV8), together with inadequate immune 
regulation and chronic antigenic stimulation as a result of other infections.  HIV associated 
NHL affects a small number of individuals and is not responsible for the NHLs in older 
individuals and females (Chiu & Weisenburger 2003). 
 
Patients with diseases of the immune system are also at increased risk of developing NHL 
(Chiu & Weisenburger 2003).  These conditions include: Sjögren’s syndrome, rheumatoid 
arthritis, coeliac disease and systemic lupus erythematosus (Chiu & Weisenburger 2003; 
Zhong 2006).  The above conditions are rare and are not thought to contribute much to the 
rise in NHL incidence (Cawson & Odell 2008; Chiu & Weisenburger 2003). 
 
2.3.5 Familial aggregation 
A positive family history of haemato-lymphoid neoplasms has very often been shown to 
increase the NHL risk by two to three times.  This association is said to be stronger than 
the other proposed risk factors.  Lymphomas can also occur within families as a result of 
common environmental factors such as occupational exposure and pesticides.  One report 
found that a low intake of vitamin C and carotene lead to an increased risk of NHL, 
especially in individuals with a positive family history of mainly haemato-lymphoid 
neoplasms.  Another report found an association between alcohol consumption and an 
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increased risk of NHL, however this was only found to affect males with a positive family 
history of haemato-lymphoid neoplasms.  These findings show a link between NHL and 
genetic and environmental factors.  Familial predisposition accounts for less than 5% of 
NHL cases and does not explain the rapidly increasing NHL incidence (Chiu & 
Weisenburger 2003).  
 
2.3.6 Blood transfusion 
Blood transfusion as a cause of NHL shows contradictory findings in the literature and 
further investigation on this subject is required to come to a definitive conclusion (Chiu & 
Weisenburger 2003). 
 
2.3.7 Agricultural and pesticide exposures 
The use of phenoxyacetic acid herbicides, fertiliser and organophosphate insecticides has 
been shown to lead to increased NHL risk.  Pesticides specifically have been shown to be 
linked to SLL and FL (Chiu & Weisenburger 2003).  
 
2.3.8 Occupation 
Numerous occupations including pathologists, chemists, anaesthesiologists, dry cleaners, 
petroleum refinery workers, rubber workers, benzene workers and farmers have been 
linked to the increased incidence of NHL.  The common agents in the abovementioned 
occupations include exposure to chemicals that are said to lead to increase in NHL 
incidence.  One study reported occupational exposure to account for up to 11% of NHLs.  
The general public may also be exposed to many chemicals but at much lower doses (Chiu 
& Weisenburger 2003). 
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2.3.9 Genetic susceptibility  
Genetic susceptibility is associated with genes relevant to metabolic enzymes as well as 
genes relevant to immune function (Chiu & Weisenburger 2003). 
 
2.3.10 Lifestyle factors 
Consumption of fruits, vegetables rich in carotene and vegetables of the cabbage family 
have shown a decreased risk of developing NHL, while consumption of meat, fat and 
animal protein are associated with increased risk of NHL.  Contradictory information has 
been found with alcohol consumption, cigarette smoking, use of hair dyes, exposure to UV 
radiation, physical activity and the risk of NHL.  Newer epidemiologic studies including 
the role of lifestyle factors on NHL have also been inconclusive (Chiu & Weisenburger 
2003).  
 
The AIDS epidemic, improved access to medical care and enhanced diagnostic tools are 
said to only account for one-third of the rise in the NHL incidence (Chiu & Weisenburger 
2003; Zhong 2006).  The cause for the remaining fraction of the increase in the NHL 
incidence is not entirely understood, however the abovementioned factors are said to play 
some role in the aetiology of NHLs (Chiu & Weisenburger 2003). 
 
2.4 Age range of lymphomas 
Both HL and NHL have a wide age range (Farman, Nortje & Wood 1993).  HL has two 
peaks: 15-35 years and after 50 years (Etemad-Moghadam et al. 2010).  NHL affects 
individuals of any age and its incidence increases throughout life (Kolokotronis et al. 
2005).  However, it is more common in adulthood than in childhood (Etemad-Moghadam 
et al. 2010) and is rare before the age of ten years and peaks in the seventh decade of life 
16 
 
(Farman, Nortje & Wood 1993).  A study by Etemad-Moghadam et al. (2010) entitled 
“Head and neck NHL: a 20 year demographic study of 381 cases” found an age range of 
seven months to 98 years.  It is age ranges like these that lead to a younger mean age like 
46.3 years in this case.  However, in most NHL studies the mean age is above 50 years 
(Sӧderholm et al. 1990; Kolokotronis et al. 2005; Kemp et al. 2008).  NHL is typically a 
disease of the elderly, with the median age of most subtypes being in the sixth or seventh 
decade (Huh 2012).  However, the exception is BL and precursor NHL (Huh 2012).   
 
The incidence of NHL increases in males and females (at a lower rate than males) but 
continues in males, and in females it decreases at 80 years and over (Huh 2012).  Mucosa-
associated lymphoid tissue lymphoma (MALT lymphoma), FL and NK/T-cell lymphoma 
usually affect a younger age group when compared to the other mature NHLs (Huh 2012). 
 
HL differs from NHL in that it has many specific age-incidence trend curves, which are 
dictated by the socio-economic status of a population (Huh 2012).  In underdeveloped 
countries, an early childhood peak is seen and mixed cellularity classic HL is the prevalent 
subtype (Huh 2012).  This peak is followed by an adult peak of > 50 years of age (Huh 
2012).  Mixed cellularity classic HL is associated with socio-economically disadvantaged 
children, which are at increased risk of early childhood infection, and the older adult 
population that are immunocompromised as a result of age or HIV and AIDS (Huh 2012).  
In developed countries, a young adult peak is observed with nodular sclerosis classic HL 
being the prevalent subtype (Huh 2012).  This peak is followed by an older adult peak 
(Huh 2012).  The nodular sclerosis classic HL subtype is associated with a higher socio-
economic background and therefore leading to delayed exposure to childhood infections, 
resulting in a young adult peak (Huh 2012). 
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2.5 Gender distribution 
Lymphomas usually have a slight male predominance (van der Waal et al. 2005) and this is 
seen in many studies (Bussu et al. 2013; Iguchi et al. 2012).  However some head and neck 
and oral NHL studies have found equal sex distribution (Bennett et al. 1974 as cited by 
Hart et al. 2004) while others have found no significant sex predilection (Urquhart et al. 
2001 as cited by Kemp et al. 2008). 
 
NHL has a male predominance with the exception of MALT lymphoma and nodular 
sclerosis classic HL, which have a female predominance (Huh 2012).  HL has an overall 
male predominance; however the different age groups have specific gender predominance 
(Huh 2012).  In developed countries, the young adult peak and prevalent nodular sclerosis 
classic HL subtype is associated with a female predominance (Huh 2012).  In developing 
countries, the early childhood peak and prevalent mixed cellularity classic HL subtype is 
associated with a male predominance (Huh 2012). 
 
Anatomic sites also have specific gender predominance, for example the salivary glands 
and thyroid gland are said to show a predominance of NHL in females (Vega, Lin & 
Medeiros 2005).  This could be due to the fact that MALT lymphoma is a common subtype 
in both these sites (Beasley 2012). 
 
2.6 Clinical features 
Clinical features are usually related to the affected anatomic site.  However, the typical 
clinical appearance is that of a growing mass that may or may not be ulcerated with the 
lesions generally being asymptomatic but pain, fever or weight loss can occur (Etemad-
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Moghadam et al. 2010; Kemp et al. 2008; Triantafillidou et al. 2012).  Triantafillidou et al. 
(2012) found that the oral lesions often show rapid growth and can spread to affect the 
underlying bone.  Kolokotronis et al. (2005) in his study found that the overlying tissues 
appeared either normal in colour, red or red-blue. 
 
2.7 B symptoms/systemic symptoms 
Lymphomas can cause generalised systemic symptoms, which can be seen in both HL and 
NHL and it generally indicates a poorer prognosis.  B symptoms include systemic 
symptoms such as night sweats, more than 10% weight loss over the past six months, 
unexplained fever greater than 38ºC, fatigue and pruritus (Kolokotronis et al. 2005; 
Triantafillidou et al. 2012).  B symptoms are more common in HLs compared to NHLs 
(accounting for 41% and 27% respectively) (Triantafillidou et al. 2012).  It is rare in NHL 
patients and is said to co-exist in approximately 15-20% of patients (Kolokotronis et al. 
2005).  van der Waal et al. (2005) mentioned that B symptoms hardly occur in the oral 
cavity.  Most NHL studies of the head and neck region showed the incidence of B 
symptoms to be between 8-16% (Hart et al. 2004; Kolokotronis et al. 2005; van der Waal 
et al. 2005).   
 
2.8 Radiographic features 
Determining if the lymphoma originated from hard or soft tissue can pose a challenge; 
however clinical or radiographic bone involvement does assist in determining the site of 
origin (Kemp et al. 2008).  Kemp et al. (2008) used radiographic imaging (to indicate bone 
destruction) in their study in order to confirm the site of origin to be bone even if there was 
soft tissue involvement.  Radiographic images of NHLs of the jaw are non-specific, usually 
showing diffuse bone destruction, either as a solitary defect, lowering of alveolar bone 
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margin or disappearance of lamina dura (Kolokotronis et al. 2005; Zhong 2006).  Other 
radiographic findings include a mixed radiolucent-radiopaque appearance due to 
osteoblastic activity and bone resorption (Kolokotronis et al. 2005).  Triantafillidou et al. 
(2012) described radiographic intra-osseous lesions to appear as radiolucent areas, either 
multilocular or unilocular and with diffuse borders. 
 
2.9 Most common anatomic site 
Due to the findings of various studies, it has been accepted that WR is the most common  
extranodal site in the head and neck region (Kolokotronis et al. 2005; Scherfler et al. 2012; 
van der Waal et al. 2005).  The tonsils have been found to be the most common sub-site 
within WR (Kolokotronis et al. 2005; Etemad-Moghadam et al. 2010; Hart et al. 2004; 
Jacobs & Hoppe 1985).  Following WR, the oral cavity and salivary glands are the most 
common sites for lymphomas of the head and neck region (Kolokotronis et al. 2005; 
Etemad-Moghadam et al. 2010; Jacobs & Hoppe 1985).  The palate is the most common 
oral site and the parotid gland followed by the submandibular gland is the most commonly 
involved salivary gland (Kolokotronis et al. 2005). 
 
2.10 Most common histological subtype 
Various authors have found DLBCL to be the most common NHL subtype of the head and 
neck region (Ota et al. 2014; Scherfler et al. 2012; Iguchi et al. 2012; Kolokotronis et al. 
2005).   
 
2.10.1 Lymphomas of B-cell origin 
The majority of the primary extranodal NHLs are of B-cell lineage, however the cause of 
this is unknown (van der Waal et al. 2005).  Hashimoto et al. (1982) (as cited by Sirsath et 
20 
 
al. 2014) concluded that lymphomas of B-cell origin are the most common histological 
subtypes of the oral cavity.  Histological NHL subtypes of B-cell origin are said to be quite 
common in the head and neck region and the subtypes include DLBCL, MALT lymphoma, 
mantle cell lymphoma, FL, BL/leukaemia and SLL/chronic lymphocytic leukaemia (CLL) 
(Triantafillidou et al. 2012).   
 
2.10.1.1 Diffuse large B-cell lymphoma (DLBCL) 
DLBCL is a clinical and biological heterogeneous subtype (Cabanillas 2011).  It has two 
large categories: Activated B-cell type (associated with poor prognosis) and Germinal 
centre B-cell type (associated with good prognosis) (Cabanillas 2011).  It is well known 
that DLBCL is the most common aggressive lymphoma (Hennessy, Hanraham & Daly 
2004), however it is treatable and has a variable clinical course of painful or painless 
swelling, either with or without ulceration (Triantafillidou et al. 2012).  The aggressive 
lymphomas usually affect the proliferating precursor lymphocytes (centroblasts, 
immunoblasts, lymphoblasts) (Hennessy, Hanraham & Daly 2004).   
 
According to van der Waal et al. (2005), DLBCL accounts for about 40% of adult 
lymphomas and according to Scherfler et al. (2012) it accounts for about 20-30% of all 
NHLs in adults and occurs in about 40% of extranodal sites.   Xie, Pittaluga & Jaffe (2015) 
reported DLBCL as the most common lymphoma, representing 30-40% of adult NHL 
worldwide.  DLBCL develops in 2-8% of patients with CLL (Triantafillidou et al. 2012). 
 
Most intra-oral soft tissue and jaw lymphomas are DLBCLs (Triantafillidou et al. 2012).  
Approximately 70-80% of lymphomas of WR are DLBCLs and this is more so for patients 
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with localised disease (Triantafillidou et al. 2012).  In the Western countries, DLBCL is a 
common lymphoma subtype of the sinonasal tract (Kanumuri et al. 2014). 
 
DLBCL is also the most common lymphoma subtype of the head and neck region in 
immunocompetent individuals however other subtypes do occur (Sirsath et al. 2014).  The 
broad heading of “DLBCL” encompasses a large number of entities based on distinct 
clinical, pathologic or biologic features (WHO classification of tumours of haematopoietic 
and lymphoid tissues (2008) as cited by Xie, Pittaluga & Jaffe (2015)).  These include 
amongst others: 
 EBV-positive DLBCL of the elderly 
This subtype affects the elderly (over 50 years).  Patients are EBV positive and one 
of the common sites affected is the tonsil (Bacon 2010). 
 Primary DLBCL of the CNS  
These are aggressive lymphomas of the brain appearing as single or multiple 
lesions (Bacon 2010).  Those affecting the immunocompromised patients are EBV 
positive as well (Bacon 2010). 
 
2.10.1.2 Plasmablastic lymphoma (PBL) 
This is an aggressive B-cell neoplasm that shows plasmacytic differentiation, originates in 
the oral cavity and tends to involve the gingiva and can infiltrate bone (Vega, Lin & 
Medeiros 2005).  The WHO classification (Stein et al. 2008) lists PBL as a variant of 
DLBCL.  Due to the relatively high frequency of PBLs in South Africa, especially in HIV-
positive individuals (Chetty et al. 2003; Chetty, Sudi & Abayomi 2012), I have chosen to 
discuss this entity separately.   
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This NHL subtype has been said to classically present as a lymphoma of the oral cavity, 
and is associated with HIV and AIDS or immunosuppression and EBV positivity (Bacon 
2010; Elyamany, Al Mussaed & Alzahrani 2015).  Sirsath et al. (2014) reported that the 
rate of EBV positivity is almost 100% in oral HIV associated PBLs and that PBL is the 
most common subtype in immunocompromised patients.  In their study half the patients 
with PBL were HIV positive.  According to Kemp et al. (2008) this is a rare subtype and 
fewer than 60 cases have been reported in the literature.  EBV association with PBLs is 
greater than with HHV8 (Castillo, Pantanowitz & Dezube, 2008).  Whilst there have been 
isolated reports of HHV8 infection in PBLs (Goedhals, Beukes & Hardie, 2008), HHV8 is 
continuously absent in most PBLs (Sirsath et al. 2014).   
 
PBLs have been reported to occur in immunocompetent patients as well as in HIV negative 
patients (Elyamany, Al Mussaed & Alzahrani 2015).  In addition to the oral cavity PBL is 
also increasingly being described in several others sites, such as the gastrointestinal tract, 
omentum, lung, nasal and paranasal regions, testes, bones, soft tissue, lymph nodes, bone 
marrow, skin, CNS and sacrococcygeal area (Elyamany, Al Mussaed & Alzahrani 2015). 
PBL has a poor prognosis with most patients dying within 2 years from initial presentation, 
and there are very few long-term survivors (Elyamany, Al Mussaed & Alzahrani 2015). 
 
2.10.1.3 Mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) 
Extranodal marginal zone lymphoma is commonly called MALT lymphoma when they 
affect mucosa-associated lymphoid tissue (Kemp et al. 2008).  They usually occur in 
tissues with chronic inflammation and sometimes chronic reactive hyperplastic lesions due 
to their genetic aberrations (Kemp et al. 2008).  Typically however, they occur as a result 
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of Sjögren’s syndrome, rheumatoid arthritis or Hashimoto’s thyroiditis and occur at sites 
that produce lymphoid tissue due to autoimmune diseases or infections (Kemp et al. 2008).   
 
The gastrointestinal tract is the most common site for MALT lymphomas, followed by the 
salivary glands (14%), head and neck (14%) and the ocular adnexa (12%) (Triantafillidou 
et al.  2012).  The common sites for MALT lymphomas in the head and neck region are the 
parotid gland, thyroid gland, WR and ocular adnexa (especially the conjunctiva) 
(Hosokawa et al. 2012).  Some authors have found the ocular adnexa to be the most 
common extranodal site for MALT lymphomas, accounting for up to 60-70% of cases (as 
cited by Triantafillidou et al. 2012).  MALT lymphomas have a tendency to involve other 
extranodal sites however the bone marrow is not often involved (Vega, Lin & Medeiros 
2005).     
 
MALT lymphomas are said to have a smooth course and spread slowly (Triantafillidou et 
al. 2012).  They are characteristically low grade and indolent in nature and therefore occur 
over prolonged periods (Hosokawa et al. 2012).  Transformation of low grade MALT 
lymphomas to high grade MALT lymphomas, namely DLBCL can occur (Vega, Lin & 
Medeiros 2005).  MALT lymphomas have a female predilection with a 1.4:1 female to 
male ratio and a mean age of 64 years (Hosokawa et al. 2012).  Head and neck MALT 
lymphomas usually involve many organs at the same time, therefore increasing the risk of 
recurrences when local measures are used for treatment (Etemad-Moghadam et al. 2010).  
Due to the indolent nature of this subtype, the prognosis is usually good in majority of the 
non-disseminated cases (Etemad-Moghadam et al. 2010); even though occasional studies 
have reported high rates of recurrences with this subtype (Vazquez et al. 2015). 
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2.10.1.4 Mantle cell lymphoma 
Mantle cell lymphoma is a rare NHL subtype, which mostly presents as nodal disease 
(Kemp et al. 2008).  Extranodal involvement is rare (Kemp et al. 2008).  Mantle cell 
lymphoma is aggressive in nature (Bacon 2010).  It has a fairly poor prognosis and mostly 
occurs in males in the seventh or eighth decade of life (Bussu et al. 2013).  Generalised 
lymphadenopathy is usually the presenting feature at diagnosis (Kemp et al. 2008).  Intra-
oral mantle cell lymphoma is rare, with the first cases occurring in the palate reported by 
Chang et al. (2003) (as cited by Kolokotronis et al. 2005) and Kolokotronis et al. (2005).  
According to Bacon (2010) in most patients that develop extranodal mantle cell 
lymphoma, the common anatomic site that is affected is WR. 
 
2.10.1.5 Follicular lymphoma (FL) 
It is well known that FL is the most common indolent lymphoma (Hennessy, Hanraham & 
Daly 2004).  Indolent lymphomas usually affect the non-dividing mature lymphocytes 
(Hennessy, Hanraham & Daly 2004).  In the USA, FL has been found to be the most 
common NHL subtype, mostly with nodal involvement, and extranodal involvement being 
rare (Kemp et al. 2008).  Even though it has an indolent nature, FL can transform to 
aggressive DLBCL and this accounts for approximately 40% of cases (Kemp et al. 2008).  
According to Armitage & Weisenburger (1998) (as cited by Scherfler et al. 2012), FL is 
the second most common form of NHL and often shows a nodal presentation.  Most 
patients present with disseminated disease at diagnosis (Scherfler et al. 2012), and many 
patients with FL relapse several times (Hennessy, Hanraham & Daly 2004). 
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2.10.1.6 Burkitt lymphoma (BL) 
BL can be divided into three categories: endemic cases in Africa, sporadic cases around the 
world and HIV associated cases (Kemp et al. 2008).  It is usually extranodal and 
commonly occurs in children and young adults (Kemp et al. 2008).  Endemic BL typically 
affects the jaws and sporadic BL usually affects the abdomen (Kemp et al. 2008).  EBV is 
very closely associated with endemic BL, occurring in almost every case however, it only 
occurs in 25% of the other BL groups (Kemp et al. 2008).  EBV has been consistently 
found in the tumour tissue of endemic BL in Africa and New Guinea (Zhong 2006).  A 
similar highly aggressive form of BL can be seen in adults (Kemp et al. 2008).  It is quite 
uncommon and is termed Burkitt-like lymphoma (Kemp et al. 2008), with morphological 
features in-between that of DLBCL and BL (Kemp et al. 2008).   
 
2.10.1.7 Small lymphocytic lymphoma (SLL)/chronic lymphocytic leukaemia (CLL) 
SLL and CLL have the same phenotype and genotype, with the only difference being their 
degree of lymphocytosis (Kemp et al. 2008).  It commonly affects patients older than 50 
years of age (Kemp et al. 2008).  Although indolent in nature, transformation to DLBCL 
occurs in about 30% of cases and is termed Richter syndrome (Kemp et al. 2008).  It is not 
common for SLL/CLL alone to develop an extranodal mass (Bacon 2010). 
 
2.10.1.8 Plasma cell tumours 
Plasma cell tumours include plasma cell myeloma, solitary plasmacytoma of bone and 
extra-osseous plasmacytoma.  The plasmacytomas are rare, and plasma cell myeloma has a 
poor prognosis (Kemp et al. 2008).  Plasma cell tumours rarely occur below the age of 40 
years (Kemp et al. 2008).  According to González et al. (1991) (as cited by Scherfler et al. 
2012), 12-15% of plasma cell myeloma cases first occur in the jaw bones and oral cavity.   
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2.10.1.8.1 Extra-osseous plasmacytomas 
Eighty percent of extra-osseous plasmacytomas occur in the head and neck with 4% being 
non-epithelial neoplasms of the nasopharynx, nasal cavity and paranasal sinuses (Vega, 
Lin & Medeiros 2005).  This subtype has a male predominance and usually occurs in 
patients over the age of 40 years with its peak in the sixth decade of life (Vega, Lin & 
Medeiros 2005).  Any site in the head and neck can be primarily involved however the 
common primary sites involved include the tonsil, sinus, nose and nasopharynx (Vega, Lin 
& Medeiros 2005).  EBV is usually not present in this subtype (Vega, Lin & Medeiros 
2005).   
 
2.10.2 T-cell and NK-cell lymphomas 
Mature T-cell and NK-cell neoplasms make up a small percentage of NHL cases 
worldwide (Kemp et al. 2008).  Extranodal NK/T-cell lymphomas are often associated 
with EBV (Kemp et al. 2008).  It is commonly seen in Asia and South America (Kemp et 
al. 2008).  The palate and the nasal cavity are the most common affected sites and while it 
does occur at other sites, it is a rare finding (Kemp et al. 2008).  T-cell lymphomas 
commonly occur nodally but may present extranodally (Bacon 2010). 
 
2.10.3 Anaplastic large cell lymphoma (ALCL) 
ALCL has two subtypes: 
 ALCL CD30-positive ALK-positive (ALK is the protein anaplastic lymphoma 
kinase) 
 ALCL CD30-positive ALK-negative 
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Both subtypes are said to be aggressive, however ALCL ALK-positive affects younger 
individuals up to 30 years of age and ALCL ALK-negative affects patients with an average 
age of 60 years (Hennessy, Hanraham & Daly 2004).  ALK-positive ALCL usually affects 
extranodal sites such as bone, soft tissues and lung (Bacon 2010). 
 
2.11 Nodal versus extranodal lymphomas 
Extranodal lymphomas of the head and neck are uncommon (Beasley 2012).  However, the 
head and neck is a more common site for extranodal NHLs than primary HLs, which are 
usually nodal (Beasley 2012). 
 
2.12 Lymphomas of Waldeyer’s Ring (WR) 
WR is made up of the tonsil, nasopharynx and base of the tongue (Beasley 2012).  
Approximately 50% of all extranodal NHLs of the head and neck occur in WR (Vega, Lin 
& Medeiros 2005).  There is a male predilection and it usually affects patients over 50 
years of age (Vega, Lin & Medeiros 2005).  These lymphomas usually present as a mass or 
an ulcer with pain, altered hearing and airway obstruction (Vega, Lin & Medeiros 2005).  
The tonsils are affected in more than half the cases, followed by the nasopharynx and the 
base of the tongue (Vega, Lin & Medeiros 2005).  Beasley (2012) found the tonsil and the 
nasopharynx to be the most common sites affected in adults and children respectively.  He 
also found that involvement of the base of the tongue only is rare.   
 
Of the WR lymphomas, 80-90% are NHL of B-cell lineage and DLBCL is the most 
common subtype (Vega, Lin & Medeiros 2005).  However, other subtypes do occur but to 
a lesser extent. Other lymphoma subtypes that have occurred in this anatomic site include 
MALT lymphoma, peripheral T-cell lymphoma, FL and mantle cell lymphoma (Vega, Lin 
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& Medeiros 2005).  HL rarely occurs at this site (Vega, Lin & Medeiros 2005).  If it does, 
the frequent subtypes are lymphocyte-rich classic HL and nodular sclerosing subtypes 
(Vega, Lin & Medeiros 2005).   
 
WR consists of normal mucosa-associated lymphoid tissue however; MALT is not the 
most common subtype (Vega, Lin & Medeiros 2005).  It is possible that these lymphomas 
are under diagnosed due to the fact that many DLBCLs are of MALT origin and 
lymphomas of WR as a result of lymphoepithelial lesions, cannot be said to be of MALT 
origin (Vega, Lin & Medeiros 2005).  
 
2.13 Lymphomas of the salivary glands 
Lymphocytes are not normally found in salivary tissue however, they do occur when there 
is inflammation (Vazquez et al. 2015).  Of the extranodal lymphomas of the head and neck, 
12% occur in the salivary glands (Beasley 2012).  The parotid gland is affected in 80% of 
cases, followed by the submandibular gland (16%), the sublingual gland (2%) and the 
minor salivary glands (2%) (Vega, Lin & Medeiros 2005).  Symptoms of salivary gland 
lymphomas include a painful or painless mass and occasionally facial nerve palsy (Vega, 
Lin & Medeiros 2005).  MALT lymphoma and DLBCL are the most common histological 
subtypes (Vega, Lin & Medeiros 2005).  Salivary gland lymphomas of MALT origin can 
be either low grade lymphomas or DLBCLs (Vega, Lin & Medeiros 2005).  Most salivary 
gland lymphomas are low grade B-cell subtypes with T-cell subtypes being very rare 
(Beasley 2012).  Low grade MALT lymphoma has been found to be the most common 
subtype to affect the salivary glands (Beasley 2012). 
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The peak incidence for salivary gland lymphomas is the seventh decade (Beasley 2012).  
Adults are mainly affected with a male:female (M:F) ratio of 1:2 (Vega, Lin & Medeiros 
2005; Kojima et al. 2007 as cited by Etemad-Moghadam et al. 2010),  however, some 
studies found an almost equal sex distribution (Roh, Huh & Moon 2007; Dunn et al. 2004 
as cited by Etemad-Moghadam et al. 2010).  The reason for the female predominance is 
not really known however, what is known is that of the total percentage of patients affected 
by autoimmune diseases, 78% are women (Vazquez et al. 2015).  This includes Sjögren’s 
syndrome which could possibly be the cause (Vazquez et al. 2015).  
 
Myoepithelial sialadenitis (a benign lymphoepithelial lesion which is a reactive salivary 
gland infiltrate of Sjögren’s syndrome) is said to be a precursor lesion of NHL and can lead 
to MALT lymphoma (Vega, Lin & Medeiros 2005; Beasley 2012).  It has been found that 
20% of patients with salivary gland lymphomas have Sjögren’s syndrome (Vega, Lin & 
Medeiros 2005).  Patients with the above mentioned conditions are approximately 43.8 
times more at risk of developing NHL compared to normal healthy individuals (Vega, Lin 
& Medeiros 2005).  Patients not suffering from Sjögren’s syndrome generally are affected 
by the FL subtype (Beasley 2012).  
 
The parotid gland has many lymph nodes around the gland as well as within the 
parenchyma and therefore lymphomas of salivary glands may be nodal or extranodal in 
origin (Vega, Lin & Medeiros 2005).  Salivary gland lymphomas arising in Warthin’s 
tumour are rare and have been reported in only about 20 cases (Vega, Lin & Medeiros 
2005).  The histological subtypes associated with Warthin’s tumour include DLBCL, FL 
and SLL, with MALT lymphoma being quite rare, and commonly occurring as nodal 
disease (Vega, Lin & Medeiros 2005).    
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2.14 Lymphomas of the jaws 
NHL of the jaws is quite rare (with the exception of BL) however; it is the most frequent 
site of osseous lymphomas compared to all the other craniofacial bones (Djavanmardi et al. 
2008).  They have an incidence rate of about 5% in extranodal sites (Etemad-Moghadam et 
al. 2010).  Lymphomas of the jaws are usually seen in adults between the ages of 40-50 
years (Djavanmardi et al. 2008).  These neoplasms may be either primary, with the jaw 
being the site of origin of the lymphoma or secondary, as a result of metastatic disease 
(Djavanmardi et al. 2008).   
 
According to Kolokotronis et al. (2005), there is conflicting data with regards to the 
prevalence of lymphomas in the jaw.  Agrawal, Agrawal & Kambalimath (2011) stated 
that the maxilla is the most prevalent jaw site.  Of the mandibular tumours, 8% are primary 
NHLs and these account for approximately 0.6% of all NHLs (Djavanmardi et al. 2008).  
More than 50% of BL cases occur in the mandible and about 15% of them occur as non-
endemic disease (Djavanmardi et al. 2008). 
 
Some of the common signs and symptoms include continuous pain and ulceration of the 
oral mucosa, tumour mass on gingiva, mobile teeth, post-extraction mass in socket, 
neurological disorders (e.g. paraesthesia) and cervical lymphadenopathy (Djavanmardi et 
al. 2008; Kolokotronis et al. 2005).  Radiographically, ill-defined borders are seen and 
bone lysis is noted in about 80% of cases (Djavanmardi et al. 2008). 
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2.15 Lymphomas of the orbit and conjunctiva 
The ocular adnexa are the second most common site for head and neck lymphomas (Vega, 
Lin & Medeiros 2005).  They usually affect elderly individuals and have a slight female 
predilection (Vega, Lin & Medeiros 2005).  Orbital involvement is seen in 60-70% of 
cases, followed by the conjunctiva in 10-20% of cases (Vega, Lin & Medeiros 2005).  
Bilateral involvement occurs in 10-15% of cases (Vega, Lin & Medeiros 2005).    
 
Clinical features include swelling, pain, proptosis, opthalmoplegia, distorted vision, 
conjunctival chemosis and slow onset erythema (Triantafillidou et al. 2012; Vega, Lin & 
Medeiros 2005).  Systemic symptoms are rare however; they are more often seen in 
patients with diffuse and high grade lymphomas (Gerbino et al. 2014).  Majority of these 
lymphomas are low grade (Gerbino et al. 2014).  MALT lymphomas comprise 60-70% of 
the lymphomas involving these sites (Vega, Lin & Medeiros 2005).  Other common 
subtypes include FL, DLBCL, mantle cell lymphoma and lymphoplasmacytic lymphoma 
(Gerbino et al. 2014).  MALT lymphomas have the best prognosis whereas mantle cell 
lymphomas are usually fatal (Gerbino et al. 2014).  Common sites for dissemination of 
orbital lymphomas include lymph nodes, bone marrow, the skin and spleen (Gerbino et al. 
2014).  There is said to be an association between Chlamydia psittaci and ocular 
lymphomas as well as a regression following antibiotic therapy (Vega, Lin & Medeiros 
2005).     
 
2.16 Lymphomas of the larynx 
Lymphoma of the larynx is a rare entity (Vega, Lin & Medeiros 2005).  However, some of 
the subtypes frequently found at this site include plasmacytoma, MALT lymphoma and 
DLBCL (Vega, Lin & Medeiros 2005).  Symptoms of laryngeal lymphomas are dysphonia, 
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dysphagia, cough, hoarseness or even the feeling of a lump in the throat (Vega, Lin & 
Medeiros 2005).  Plasmacytoma at this site presents as a unilateral, smooth, non-ulcerated 
mass and commonly occurs in the epiglottis (Vega, Lin & Medeiros 2005).   
 
2.17 Sinonasal tract lymphomas 
Sinonasal tract lymphomas are rare neoplasms of the head and neck region (Kanumuri et 
al. 2014).  In the Western countries DLBCL is a common subtype of this site and is more 
common in the paranasal sinuses and rare in primary nasal neoplasms (Abbondanzo & 
Wenig 1995; Fellbaum, Hansmann & Lennert 1989; Woo et al. 2004 and Cuadra-Garcia et 
al. 1999 all cited by Kanumuri et al. 2014).  A study by Kanumuri et al. (2014) was 
consistent with what is reported in the literature (Abbondanzo & Wenig 1995; Fellbaum, 
Hansmann & Lennert 1989; Woo et al. 2004 and Cuadra-Garcia et al. 1999 all cited by 
Kanumuri et al. 2014), with DLBCL accounting for 65.9% of the paranasal lymphomas 
and 34% of the nasal cavity lymphomas.  DLBCL is usually less aggressive compared to 
the other subtypes found in this site (Abbondanzo & Wenig 1995 and Logsdon et al. 1997 
as cited by Kanumuri et al. 2014) however; they have non-specific clinical presentations 
that differ between patients and geographic locations (Kanumuri et al. 2014).   
 
The sinonasal area has a complex anatomy due to the many critical structures in its 
surrounding, such as the orbit and cranial nerves, and is prone to local spread of disease 
(Kanumuri et al. 2014).  Primary neoplasms of the nasal cavity have a very poor prognosis 
(Hatta et al. 2001 as cited by Kanumuri et al. 2014).  The study by Kanumuri et al. (2014) 
differed from other reports in the literature as it showed that patients with nasal cavity 
involvement and paranasal sinus involvement had similar survival rates. 
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Many lymphoma subtypes have a male predominance however, with sinonasal tract 
lymphomas the gender predominance is unclear (Kanumuri et al. 2014).  Two studies 
found a male predominance while one found a female predominance (Kanumuri et al. 
2014).  Signs and symptoms of sinonasal lymphomas include facial swelling, nasal 
obstruction, bloody discharge or visual disturbances, and B symptoms can occur 
(Kanumuri et al. 2014).  Extranodal dissemination is the frequent cause of fatality 
especially with primary lymphomas of the nasal cavity which have a poor prognosis 
(Kanumuri et al. 2014).  However, due to the subtle symptoms of sinonasal tract 
lymphomas, they can be mistaken for benign inflammatory conditions such as upper 
respiratory tract infections and allergic rhinitis; this being seen more common in paediatric 
patients (Kanumuri et al. 2014). 
 
2.18 Extranodal NK/T-cell lymphoma-nasal type 
Extranodal NK/T-cell lymphoma as referred to as “lymphoma of nasal type” is the most 
common histological subtype of the nasal cavity and paranasal sinuses however, other 
subtypes do occur (Triantafillidou et al. 2012).  A few cases of NK/T-cell lymphoma-nasal 
type can be found in primary non-nasal sites (Coha et al. 2014).  This lymphoma subtype 
has a tendency to involve various extranodal sites, especially the nasopharynx, nasal cavity 
and palate (Vega, Lin & Medeiros 2005).    
 
It is said that most of these neoplasms are of NK-cell lineage and a few of T-cell origin and 
thereby the name (Vega, Lin & Medeiros 2005).  The median age is usually around 50 
years and has a slight male predominance (Coha et al. 2014).  The common symptoms of 
this subtype are nasal mass, nasal obstruction, chronic rhinorrhoea or epistaxis (Coha et al. 
2014; Beasley 2012).  Some of the primary sites affected include the nasopharynx, nasal 
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cavity, paranasal sinuses, larynx and tonsils (Coha et al. 2014).  Spread of tumour to the 
hard palate, orbit, soft tissue and bone can occur (Coha et al. 2014).  This subtype is 
responsible for extensive destruction of the vasculature as well as tissue necrosis and has 
an aggressive clinical course (Coha et al. 2014).  Metastasis to regional nodes and distant 
organs is also reported (Coha et al. 2014).  Common metastatic sites include the 
gastrointestinal tract, lungs, skin and testes (Coha et al. 2014).  Bone marrow is not usually 
affected (Vega, Lin & Medeiros 2005).  CNS involvement is rare (Beasley 2012).  Relapse 
remains localised but generally occurs at extranodal sites (Beasley 2012; Vega, Lin & 
Medeiros 2005).        
 
This subtype is commonly seen in South and Central America as well as East Asia 
(Beasley 2012) and is rare in the European population (Coha et al. 2014).  A strong 
genetic/racial predisposition is linked to this subtype due to the high incidence in Asians 
that migrated to North America (Beasley 2012).  There is a strong link with this subtype 
and EBV (Beasley 2012).  A high frequency of the hepatitis B-cell carrier has been found 
in some areas where this lymphoma subtype is highly prevalent (Beasley 2012).  An 
association between this subtype and haemophagocytic syndrome was also found (Vega, 
Lin & Medeiros 2005).    
 
2.19 Cutaneous lymphomas of the head and neck 
Certain histological subtypes of primary cutaneous lymphomas are seen more often than 
others in the head and neck region and these include some subtypes of DLBCL, MALT 
lymphoma and primary follicle-centre lymphoma (Vega, Lin & Medeiros 2005).  
Cutaneous DLBCLs in the head and neck region probably represent cutaneous expression 
of systemic lymphoma (Vega, Lin & Medeiros 2005).    
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2.20 Geographic variances 
The frequency and subtype distribution of lymphomas varies according to geographic 
location (Iguchi et al. 2012; Huh 2012).  Geographic variances in lymphoma incidence 
ratio in Japan as compared to that in Western countries include a lower incidence ratio in 
HL, and a higher incidence ratio of T/NK-cell lymphomas (especially adult T-cell 
leukaemia/lymphoma and extranodal NK/T-cell lymphoma nasal type) (Iguchi et al. 2012).  
The incidence of HL in Japan is rare (4-7% of all lymphomas) compared to Western 
countries which have a reported incidence of about 40-45% (Iguchi et al. 2012).  The 
incidence of T/NK-cell lymphoma (15-20%) in Asia is also reported to be higher when 
compared to reports in Western countries (5-10%) (Iguchi et al. 2012).  The 3.3% HL 
incidence and 18% T/NK-cell lymphoma incidence reported by the Japanese study (Iguchi 
et al. 2012) is in keeping with that of previous reports.  In a similar manner to head and 
neck reports, recent Japanese large scale surveys on lymphomas of the entire body showed 
an HL incidence of 4-7% and T/NK-cell lymphoma ratios of 19-25% (Iguchi et al. 2012).  
However, B-cell lymphomas accounted for the most number of cases in both studies 
(Iguchi et al. 2012).   
 
In the Western population, DLBCL accounts for most of the sinonasal tract lymphomas; 
more commonly in the paranasal sinuses and less commonly in the nasal cavity (Kanumuri 
et al. 2014).  However in Asia, NK/T-cell lymphomas are more common in the sinonasal 
area (Kanumuri et al. 2014).  The Asian population has shown distinctly higher frequency 
rates of the subtypes T/NK-cell lymphoma and MALT lymphoma, and lower rates of FL 
and SLL/CLL when compared to the Western world (Huh 2012).  The lower rates of the 3 
subtypes cannot be explained, however the higher rates of MALT lymphoma in the Asian 
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population and T/NK-cell lymphoma in the south-eastern Japanese population stems from 
the high frequency of Helicobacter pylori and HTLV-1 respectively (Huh 2012). 
 
It is also important to note the role of environmental factors as an aetiological factor in 
lymphoma formation (Huh 2012).  An NHL study of Asians residing in the USA, grouped 
Asians into two categories: USA-born Asians and foreign born Asians (Huh 2012).  The 
study found USA- born Asians to have higher incidence rates of FL, SLL/CLL and nodular 
sclerosis classic HL.  This study supports the role of environmental factors in the aetiology 
of malignant lymphoma (Huh 2012).  
 
2.21 HIV and AIDS and lymphomas 
Lymphomas are one of three AIDS-defining cancers (Brower 2011) and can be the first 
manifestation of HIV (Sirsath et al. 2014).  These HIV associated lymphomas account only 
for 22-26% of the total number of lymphoma cases (Sirsath et al. 2014).  Over 80% of 
lymphomas that occur in HIV positive patients are high grade, mature lymphomas of B-
cell origin of both germinal centre and activated B-cell subtypes (Sirsath et al. 2014).  
These subtypes include DLBCL, BL, PBL, primary DLBCL of the CNS and primary 
effusion lymphoma (Sirsath et al. 2014). 
 
The relationship of CD4 count to the risk of developing an HIV associated lymphoma 
differs according to the lymphoma subtype (Sirsath et al. 2014).  Primary CNS lymphomas 
mostly occur in the setting of very low CD4 counts (<50mm³) while germinal centre 
DLBCLs and BLs usually occur in patients with higher CD4 counts (Sirsath et al. 2014). 
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The increase in this cancer is due to limited access to anti-retroviral therapy (ART) and 
prevention programs and therefore people in Africa that are affected with AIDS, have a 
five times higher risk of developing lymphomas (Brower 2011).  Developing countries 
have thus shown an increase in lymphoma cases due to the poor highly active anti-
retroviral therapy (HAART) coverage of patients, late commencement of treatment and 
incomplete viral suppression (Brower 2011). 
 
In general, there is minimal reported epidemiologic data on the relationship between HIV 
and AIDS and lymphoma incidence in Africa (Oluwasola et al. 2011).  African cancer 
statistics need to be utilised with caution as only eight African countries keep cancer 
registries, and record keeping is not very efficient (Brower 2011).  A Nigerian study done 
on the association between HIV and the incidence of lymphoma cases showed that from 
1991 to 2001, the HIV incidence increased from 1.8% to 5.8% and then decreased to 4.4% 
in 2005 (Oluwasola et al. 2011).  However a study on the lymphoma incidence during the 
same period showed a decrease from 58 cases to 24 cases and surgical biopsies dropped 
from 1.4% to 0.7% (Oluwasola et al. 2011).  This suggests that the HIV epidemic did not 
influence the lymphoma incidence (Oluwasola et al. 2011).  This finding was attributed to 
the fact that out of the high number of HIV positive patients in Nigeria, only a very small 
portion of patients receive HAART treatment, while the bulk of the patients have a very 
short survival rate due to acquiring opportunistic infections (Oluwasola et al. 2011).  
Therefore there is not much opportunity for a lymphoma to develop (Oluwasola et al. 
2011). 
 
The risk of CNS NHL in an AIDS patient is increased by 5000 times, of DLBCL by 100-
140 times, of BL by 100 times, and of PBL and HL by 10 times (Huh 2012). 
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Approximately 50% of the HIV positive DLBCL cases are EBV positive and about 30% of 
the HIV positive BL cases are EBV positive (Huh 2012), and there is almost 100% EBV 
positivity in HIV positive PBL cases (Sirsath et al. 2014).  HAART has shown to decrease 
the incidence of HIV related lymphomas in recent years (Huh 2012).  However, HL has 
shown an increasing incidence since the use of HAART in HIV patients, indicating that 
HL requires a healthy immune system to thrive (Huh 2012).  HIV associated PBL cases 
have a very high male predominance and a median CD4 count of about 178 cells/mm³ 
(Sirsath et al. 2014).   
 
2.22 Head and neck lymphomas in South Africa 
A study carried out in Western Cape, South Africa investigated the trends of prevalence 
and the pathological spectrum of head and neck lymphomas at the Tygerberg referral 
hospital over a five year period, as well as a possible relationship with HIV (Chetty, Sudi 
& Abayomi 2012).  This study showed that there was an overall increase in NHL cases 
over the 5 year period, which tied up with a similar increase in the HIV prevalence as well, 
and concluded that the suboptimal management using ART in HIV positive patients may 
have a direct link.  DLBCL was the largest category of NHL (32%), followed by HL 
(27%), FL (10%) and PBL (8%).  PBL and BL were only seen in HIV positive patients.  
Head and neck lymphomas presented as nodal disease in 64% of cases and as extranodal 
disease in 37% of cases.  The limitation of this study included the failure to determine HIV 
status in all records (Chetty, Sudi & Abayomi 2012). 
 
2.23 Lymphomas of children and adolescents 
Head and neck neoplasms are quite uncommon in childhood (Khademi, Taraghi & 
Mohammmadianpanah 2009).  However, lymphomas are the most common solid tumour 
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of the head and neck region in children (Dubey et al. 1998).  The incidence of lymphomas 
varies according to geographic location with equatorial Africa having a lymphoma 
incidence rate of 50% due to the high incidence of BL (Dubey et al. 1998).  Non-endemic 
BL areas have a childhood incidence rate of about 10% (Roh, Huh & Moon 2007; Dubey 
et al. 1998; Khademi, Taraghi & Mohammmadianpanah 2009).  The incidence of 
childhood malignancies, including lymphomas is on the increase in developed countries 
(Roh, Huh & Moon 2007).  The trend in the Asian population is not known; however EBV 
which is closely related to certain lymphomas, such as NK/T-cell lymphomas is endemic in 
East Asia (Roh, Huh & Moon 2007).       
 
The literature clearly shows that malignant lymphomas comprise two distinct entities (HL 
and NHL), and highlights the differences in their incidence, demographics, clinical 
features, geographic distribution, their association with different anatomic sites and its 
association with HIV.  The differences in developed and developing countries are also 
emphasised.  The results of this study will be compared to that of the literature to 
determine how South Africa compares to the rest of the world. 
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CHAPTER 3 
 
3.0  AIM 
 
The aim of this retrospective review is to evaluate the frequency and clinico-pathologic 
characteristics of patients diagnosed with head and neck lymphoma at the Department of 
Oral Pathology, University of the Witwatersrand, Johannesburg over the 20 year period,  
1993-2012. 
 
3.1 STUDY OBJECTIVES 
 
 To determine the total number of lymphoma cases diagnosed per annum during the  
       study period and to evaluate the overall frequency and prevalence of lymphoma cases   
       over the 20 year period, 1993 – 2012 
 To determine the frequency and prevalence of each subtype 
 To determine the percentage of HL versus NHL cases 
 To evaluate the male:female ratio in each sub-type 
 To determine the age range within each sub-type 
 To determine the percentage of nodal to extranodal sites of the diagnosed cases 
 To evaluate anatomical sites involved and their frequency 
 To analyse the histological type/subtype of all the head and neck lymphomas within 
       the sample in the defined 20 year study according to the 2008 WHO classification of   
       haemato-lymphoid malignancies 
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CHAPTER 4 
 
4.0  MATERIALS AND METHODS 
 
4.1 Study design and population 
This is a retrospective study of all histologically confirmed head and neck lymphomas 
diagnosed in the Department of Oral Pathology, University of the Witwatersrand, 
Johannesburg, South Africa over a 20 year period, from the 1 January 1993 until the 31 
December 2012. 
 
The study sample is thought to be reflective of the greater Johannesburg and surrounding 
areas.  The Department of Oral Pathology provides a regional wide diagnostic service to 
the Charlotte-Maxeke Johannesburg Hospital as well as to municipal community clinics, 
and other provincial hospitals within the greater Johannesburg Metropolitan and 
surrounding areas, including amongst others the Chris Hani-Baragwanath and Helen 
Joseph Hospitals.  These hospitals are tertiary academic and community referral centres for 
a large portion of the Gauteng population and serve both low and middle socio-economic 
persons with and without medical insurance.  Data collected in this retrospective analysis 
was fairly representative, minimising the possibility of bias when compared to a cross-
sectional study. 
 
4.2 Data collection  
The histopathology reports of patients diagnosed with lymphomas of the head and neck 
were reviewed in great detail.  Epidemiological data including the demographic, clinical, 
laboratory, and histological parameters for each patient were recorded on a standardised 
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data capture sheet (Appendix 1).  Variables included, amongst others, the age of patient, 
gender, site involved, size of tumour, type of lymphoma (final histological diagnosis) and 
year diagnosed. 
 
Lymphomas were classified according to the 2008 WHO Classification of Tumours of 
Lymphoid Neoplasms (refer to Appendix 2) (Swerdlow et al. 2008).  For simplification 
purposes and as traditionally described, lymphomas were divided into two main groups: 
HL and NHL.  The NHLs were further divided into B-cell, T & NK-cell neoplasms and 
precursor and mature/peripheral subtypes.  HLs were sub-classified into nodular 
lymphocyte predominant category and classic HL (CHL).  CHL was further subdivided 
into: nodular sclerosing, mixed cellularity, lymphocyte rich and lymphocyte depleted.  All 
lymphoma subtypes were correlated with age, gender and sites involved. 
 
4.3 Statistical analysis 
The data was entered into Microsoft® Excel® spread sheets, and then transferred to the 
statistical software programme Statistica for statistical analysis under the guidance of a 
biostatistician.  The Chi-square test was used to assess the trends amongst the categorical 
variables, such as amongst others gender, nodal versus extranodal, and HL versus NHL.  
The level of significance was set at 0.05. 
 
4.4 Ethical considerations 
There was no direct contact with any of the patients during this retrospective study and 
patient records and slides were given study numbers in order to maintain patient 
confidentiality.  The protection of the rights of human research subjects was respected.  
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Ethical clearance (M131043) was granted by the Human Research Ethics Committee at the 
University of the Witwatersrand, Johannesburg, South Africa (Appendix 3). 
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CHAPTER 5 
 
5.0  RESULTS 
 
5.1 Number of cases 
A 20 year review of the archives in the Oral Pathology Unit, University of Witwatersrand 
revealed a total of 22 459 patients referred to the Unit during the period 1993-2012.  Of the 
22 459 oral pathology cases, 504 of these patient cases (2.24%) were head and neck 
lymphomas.  The annual number of oral pathology cases, total number of lymphoma cases 
and the annual percentage of lymphoma cases are shown in Table 5.1 and Figure 5.1. 
 
5.2 Age 
Age was recorded in 498 patients out of the 504 patients.  The median age was 39 years 
and patients ranged in age from 2 to 100 years.   
 
5.3 Gender 
Gender was recorded in 503 patients out of the 504 patients.  267 patients (53%) were 
male, 236 (46.8%) were female and one patient had an unknown gender (0.2%)  
(M:F ratio = 1.13:1). 
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Table 5.1 Number and percentage of lymphoma cases per annum from 1993-2012 
Year Oral pathology cases (n) Lymphoma cases (n) Lymphoma cases (%) 
1993 725 6 0.83 
1994 602 3 0.50 
1995 824 2 0.24 
1996 661 3 0.45 
1997 636 3 0.47 
1998 442 2 0.45 
1999 1066 8 0.75 
2000 1134 13 1.15 
2001 1184 21 1.77 
2002 1382 19 1.37 
2003 1477 30 2.03 
2004 1380 29 2.10 
2005 1294 25 1.93 
2006 1086 32 2.95 
2007 1004 32 3.19 
2008 1124 38 3.38 
2009 1618 62 3.83 
2010 1471 56 3.81 
2011 1788 62 3.47 
2012 1561 58 3.72 
TOTAL 22 459 504 2.24 
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Figure 5.1 Comparison of number of lymphoma cases per annum from 1993-2012 
 
 
5.4 Anatomic site 
The anatomic sites are shown below in Table 5.2 and Figure 5.2.  Of the 504 lymphoma 
cases, 57% of cases (287 cases) were intra-oral sites and 43% of cases (217 cases) were 
extra-oral. 
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Table 5.2 Anatomic sites of occurrence of the head and neck lymphomas  
Anatomic site Lymphoma cases (n) Percentage (%) 
Cervical lymph node 115 22.82 
Maxilla 60 11.90 
Palate 49 9.72 
Mandible 42 8.33 
Gingiva 41 8.13 
Buccal mucosa 33 6.55 
Maxillofacial lymph node 22 4.37 
Salivary gland 18 3.57 
Waldeyer’s ring 17 3.37 
Nasal cavity 16 3.17 
Paranasal sinuses 12 2.38 
Posterior nasal space 10 1.98 
Neck 9 1.79 
Oral cavity (NOS) 7 1.39 
Jaw (NOS) 7 1.39 
Tongue 7 1.39 
Floor of mouth 6 1.19 
Buccal vestibule 6 1.19 
Submandibular area 6 1.19 
Face 4 0.79 
Oropharynx 3 0.60 
Lip 3 0.60 
Pharynx 2 0.40 
Larynx 2 0.40 
Orbit 1 0.20 
Alveolus 1 0.20 
Tonsillar fossa area 1 0.20 
Submental area 1 0.20 
Scalp 1 0.20 
Parapharynx 1 0.20 
Retromolar mucosa 1 0.20 
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Figure 5.2 Comparison of the ten most common anatomic sites of the head and neck 
lymphomas 
 
 
5.5 Lymphoma subtypes 
Table 5.3 and Figure 5.3 show the lymphoma subtypes diagnosed within the study period, 
the number of cases (n) and percentage (%) of each case. 
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Table 5.3 Head and neck lymphoma subtypes diagnosed within the study period, 1993-2012 
Lymphoma subtype Number of cases (n) Percentage (%) 
Plasmablastic lymphoma 159 31.55 
Diffuse large B-cell lymphoma 155 30.75 
Burkitt lymphoma 28 5.56 
Nodular sclerosing classic HL 21 4.17 
Nodular lymphocyte predominant HL 16 3.17 
Plasma cell myeloma 15 2.98 
Mixed cellularity classic HL 14 2.78 
Peripheral T-cell lymphoma (NOS) 12 2.38 
Small lymphocytic lymphoma 11 2.18 
Follicular lymphoma 10 1.98 
Anaplastic large cell lymphoma 10 1.98 
NK/T-cell lymphoma (nasal type) 10 1.98 
MALT lymphoma 9 1.79 
Solitary plasmacytoma of bone 7 1.39 
Extra-osseous plasmacytoma 7 1.39 
Burkitt-like lymphoma 6 1.19 
Mantle cell lymphoma 5 0.99 
B-cell NHL (NOS) 2 0.40 
Acute undifferentiated leukaemia 2 0.40 
Marginal zone lymphoma 1 0.20 
T-cell lymphoma (NOS) 1 0.20 
T-cell rich B-cell NHL 1 0.20 
T-cell acute lymphoblastic lymphoma 1 0.20 
Lymphoblastic lymphoma (NOS) 1 0.20 
Total 504 100 
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Figure 5.3 Comparison of the ten most common head and neck lymphoma histological 
subtypes 
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5.6 NHL versus HL 
Of the 504 lymphoma cases, 453 patients (90%) had NHL and 51 patients (10%) had HL 
(Figure 5.4 and Table 5.4). 
 
 
Figure 5.4 Comparison of percentage of NHL versus HL 
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Table 5.4 Distribution of the number of head and neck NHL and HL lymphoma subtypes 
Lymphoma subtype Number of cases (n) Percentage (%) 
Non-Hodgkin lymphoma   
Plasmablastic lymphoma 159 31.55 
Diffuse large B-cell lymphoma 155 30.75 
Burkitt lymphoma 28 5.56 
Plasma cell myeloma 15 2.98 
Peripheral T-cell lymphoma (NOS) 12 2.38 
Small lymphocytic lymphoma 11 2.18 
Follicular lymphoma 10 1.98 
Anaplastic large cell lymphoma 10 1.98 
NK/T-cell lymphoma (nasal type) 10 1.98 
MALT lymphoma 9 1.79 
Solitary plasmacytoma of bone 7 1.39 
Extra-osseous plasmacytoma 7 1.39 
Burkitt-like lymphoma 6 1.19 
Mantle cell lymphoma 5 0.99 
B-cell NHL (NOS) 2 0.40 
Acute undifferentiated leukaemia 2 0.40 
Marginal zone lymphoma 1 0.20 
T-cell lymphoma (NOS) 1 0.20 
T-cell rich B-cell NHL 1 0.20 
T-cell acute lymphoblastic lymphoma 1 0.20 
Lymphoblastic lymphoma (NOS) 1 0.20 
Hodgkin lymphoma   
Nodular sclerosing classic HL 21 4.17 
Nodular lymphocyte predominant HL 16 3.17 
Mixed cellularity classic HL 14 2.78 
Total 504 100 
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Of the 453 NHL cases: 
 416 cases were of B-cell origin (91.83%) 
 35 cases were of NK/T-cell origin (7.73%) 
 1 case was of ambiguous lineage (0.22%) 
 1 case was of unknown origin (0.22%) 
 
The 453 NHL cases were further categorised: 
 1 case of ambiguous lineage (0.22%) 
 2 cases being precursor neoplasms (0.44%) 
 450 cases being mature neoplasms (99.34 %) 
 
From all the NHL cases (453 cases), 448 patients had known ages.  The median age was 40 
years and the age range was 2 to 100 years.  From the 51 HL cases, 50 patients had ages 
recorded.  The median age was 30 years and the age range was 12 to 58 years. 
 
Of the 453 NHL patients, 244 (53.86 %) were males and 208 (45.92 %) were females and 
one patient had an unknown gender (0.22%).  Of the 51 HL patients, 23 (45%) were males 
and 28 (55%) were females.  There was no statistically significant difference between the 
percentage of males and females in NHL and HL (p=0.23). 
 
The most common NHL was PBL (31.55%) and the most common HL was nodular 
sclerosing classic HL (4.17%).  Of all the NHLs the most common lymphoma of B-cell 
origin was PBL (31.55%) and the most common lymphoma of T-cell origin was peripheral 
T-cell lymphoma (NOS) (2.38%). 
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5.6.1 B-cell lymphomas 
Of the 159 PBLs, 104 patients (65.41%) were male and 55 patients (34.59%) were female.  
The median age was 39 years with an age range of 11 to 84 years.  PBLs occurred more 
commonly intra-orally, with132 cases (83.02%) occurring in oral sites and 27 cases 
(16.98%) in extra-oral sites; 31 cases (19.50%) occurred in the maxilla, 26 cases (16.35%) 
in the palate, 22 cases (13.84%) in the gingiva, 18 cases (11.32%) in the mandible, 17 
cases (10.69%) in the buccal mucosa, 5 cases each (3.14%) in the cervical lymph node, 
nasal cavity and the oral cavity (NOS), 4 cases each (2.52%) in the posterior nasal cavity 
and paranasal sinuses, 3 cases each (1.89%) in the floor of the mouth and the buccal 
vestibule, 2 cases each (1.26%) in the salivary glands, lip, maxillofacial lymph node, face 
and tongue, and 1 case each (0.63%) in WR, pharynx, alveolus, jaw (NOS), larynx and 
submandibular area.  
 
DLBCL occurred in 155 cases, 74 patients (47.74 %) were male, and 80 patients (51.61%) 
were female and one patient had an unknown gender (0.65%).  Of the 155 DLBCL cases, 
age was documented for 152 patients.  The median age was 40 years with an age range of 3 
to 92 years.   
 
Oral involvement was seen in 71 DLBCL cases (45.81%), and 84 cases (54.19%) occurred 
in extra-oral sites.  These included 43 cases (27.74%) occurring in the cervical lymph 
nodes, 14 cases (9.03%) in WR, 12 cases (7.74%) in the gingiva, 11 cases each (7.10%) in 
the palate, salivary glands and maxillofacial lymph nodes, 7 cases each (4.52%) in the 
maxilla and the mandible, 6 cases (3.87%) in the neck, 5 cases (3.23%) in the buccal 
mucosa, 4 cases (2.58%) in the posterior nasal space, 3 cases each (1.94%) in the nasal 
cavity, buccal vestibule, jaw (NOS), submandibular area and the tongue, 2 cases (1.29%) 
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in the oropharynx, and 1 case each (0.65%) in the floor of the mouth, paranasal sinuses, 
oral cavity (NOS), pharynx, tonsillar fossa area, face and larynx. 
 
BL occurred in 28 cases of which 6 cases were atypical BL.  Of the 28 BL cases, 13 
patients (46.43%) were male and 15 (53.57%) were female.  Age was recorded in 27 
patients.  The median age was 28 years and the age range was 2 to 59 years.  Orally, there 
were 22 (78.57%) BL cases, and 6 cases (21.43%) occurred in extra-oral sites; 9 cases 
(32.1%) occurred in the mandible, 6 (21.4%) in the maxilla, 3 (10.7%) in the buccal 
mucosa, 2 each (7.1%) in the jaw (NOS) and cervical lymph nodes, and 1 each (3.6%) 
affecting the gingiva, maxillofacial lymph node, submandibular area, posterior nasal space, 
paranasal sinuses and oral cavity (NOS). 
  
Plasma cell myeloma occurred in 15 patients, 7 patients (46.67%) were male and 8 
(53.33%) were female.  Age was recorded in all 15 patients.  The median age was 52 years 
and the age range was 26 to 77 years.  Orally, there were 11 cases (73.33%), and 4 cases 
(26.67%) occurred at extra-oral sites; 5 cases (33.33%) occurring in the maxilla, 3 (20%) 
in the mandible, 2 (13.33%) in the paranasal sinuses and 1 each (6.67%) in the palate, 
buccal mucosa, nasal cavity, gingiva and the scalp.  
 
SLL occurred in 11 patients, with 6 patients (54.55%) being male and 5 patients (45.45%) 
female.  Age was recorded in all patients.  The median age was 62 years and the age range 
was 24 to 85 years.  This subtype occurred in 4 oral sites (36.36%) and 7 (63.64%) extra-
oral sites, and 5 cases (45.45%) occurred in the cervical lymph nodes, 2 (18.18%) in the 
tongue and 1 each (9.10%) in the maxilla, maxillofacial lymph node, jaw (NOS) and 
parapharynx. 
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FL occurred in 10 patients, 6 males (60%) and 4 females (40%).  All patient ages were 
recorded.  The median age was 54 years and the age range was 36 to 82 years.  This 
subtype occurred in 2 oral sites (20%) and 8 extra-oral sites (80%), and 6 cases (60%) 
occurred in the cervical lymph nodes and 2 each (20%) in WR and the maxillofacial lymph 
nodes. 
 
MALT lymphoma occurred in 9 patients, 2 males (22.22%) and 7 females (77.78%).  Age 
was recorded in all 9 patients.  The median age was 61 years and the age range was 46 to 
78 years.  This subtype occurred in 5 oral sites (55.56%) and 4 extra-oral sites (44.44%), 
and 4 cases (44.44%) occurred in the salivary glands, 3 (33.33%) in the palate and 1 each 
(11.11%) in the buccal mucosa and mandible. 
 
Solitary plasmacytoma of bone occurred in 7 patients, 3 males (42.86%) and 4 females 
(57.14%).  Age was recorded in all 7 patients.  The median age was 50 years and the age 
range was 12 to 100 years.  All 7 cases occurred in the oral cavity, with 3 cases (42.86%) 
occurring in the maxilla and 2 each (28.57%) in the palate and mandible.   
 
Extra-osseous plasmacytoma occurred in 7 patients, 3 males (42.86 %) and 4 females 
(57.14%).  Age was recorded in all 7 cases.  The median age was 52 years and the age 
range was 42 to 65 years.  This subtype occurred in 4 oral sites (57.14%) and 3 extra-oral 
sites (42.86%), and 3 cases (42.86%) occurred in the nasal cavity, 2 (28.57%) in the 
gingiva and 1 each (14.29%) in the maxilla and the retromolar mucosa. 
 
Burkitt-like lymphoma occurred in 6 patients, 1 male (16.67 %) and 5 females (83.33%).  
Age was recorded in all 6 patients.  The median age was 32 years and the age range was  
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5 to 59 years.  This subtype occurred in 3 oral sites (50%) and 3 extra-oral sites (50%), and 
1 case each (16.67%) occurred in the cervical lymph node, buccal mucosa, orbit, mandible, 
paranasal sinuses and the submandibular area.  
 
Mantle cell lymphoma occurred in 5 patients, 4 males (80%) and 1 female (20%).  Age 
was recorded in all 5 patients.  The median age was 57 years and the age range was 41 to 
73 years.  This subtype occurred in 2 oral sites (40%) and 3 extra-oral sites (60%), and 2 
cases (40%) occurred in the cervical lymph nodes and 1 case each (20%) in the buccal 
mucosa, lip and posterior nasal space. 
 
B-cell NHL (NOS) occurred in 2 patients, both patients being female.  The median age was 
38.5 years and age range was 33 to 44 years.  Both cases occurred in oral sites, one case in 
the mandible and one in the floor of the mouth. 
 
Marginal zone lymphoma occurred in 1 patient which was a female.  She was 88 years old 
and it occurred in an extra-oral site which was the cervical lymph node. 
 
5.6.2 T-cell lymphomas and NK/T-cell lymphomas 
Peripheral T-cell lymphoma (NOS) occurred in 12 patients, with 4 patients (33.33%) being 
male and 8 patients (66.67%) female.  Age was recorded in all patients.  The median age 
was 35.5 years and the age range was 11 to 55 years.  This subtype occurred equally in oral 
and extra-oral sites (6 cases each [50%]), and 2 cases each (16.67%) were found in the 
cervical lymph node, palate and maxilla and 1 case each (8.33%) in the neck, nasal cavity, 
gingiva, maxillofacial lymph node, submental area and oropharynx. 
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Anaplastic large cell lymphoma occurred in 10 patients, 8 males (80%) and 2 females 
(20%).  Age was recorded in 9 patients.  The median age was 24 years and the age range 
was 4 to 60 years.  This subtype occurred in 6 oral sites (60%) and 4 extra-oral sites (40%), 
and 3 cases (30%) occurred in the cervical lymph nodes, 2 each (20%) in the buccal 
mucosa and gingiva and 1 each (10%) in the maxilla, floor of mouth and neck. 
 
NK/T-cell lymphoma (nasal type) occurred in 10 patients, 6 males (60%) and 4 females 
(40%).  All ages were recorded.  The median age was 36.5 years and the age range was 16 
to 61 years.  This subtype occurred in 4 oral sites (40%) and 6 extra-oral sites (60%), and 3 
cases (30%) occurred in the nasal cavity and 2 each (20%) in the palate, maxilla, paranasal 
sinuses and 1 case (10%) in the face. 
 
T-cell lymphoma (NOS) occurred in a single patient, a 69 year old female in an oral site, 
the maxilla.  T-cell rich B-cell NHL occurred in a single patient, a 31 year old male in an 
extra-oral site, a salivary gland. 
 
5.6.3 HL 
Nodular sclerosing CHL occurred in 21 cases, 7 patients (33.33%) were male and 14 
(66.67%) were female.  The median age of the 21 patients was 32 years and the age range 
was 12 to 47 years.  All 21 cases (100%) occurred in extra-oral sites, 20 cases (95.24%) 
occurred in the cervical lymph nodes and 1 case (4.76%) occurred in a maxillofacial lymph 
node.  
 
Nodular lymphocyte predominant HL occurred in 16 patients, with 10 patients (62.5%) 
being male and 6 (37.5%) female.  Age was recorded in 15 out of the 16 patients.  The 
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median age was 27 years and the age range was 14 to 51 years.  All 16 cases (100%) 
occurred at extra-oral sites, 13 (81.25%) affecting the cervical lymph nodes and 3 
(18.75%) affecting the maxillofacial lymph nodes. 
 
Mixed cellularity CHL occurred in 14 patients, with 6 patients (42.86%) being male and 8 
(57.14%) female.  Age was recorded in all patients.  The median age was 33 years and the 
age range was 17 to 58 years.  This subtype occurred in 3 oral sites (21.43%) and 11 
(78.57%) extra-oral sites; 11 cases (78.57%) occurred in the cervical lymph node and 1 
each (7.14%) in the palate, buccal mucosa and neck. 
 
5.6.4 Precursor lymphoid neoplasms 
T-cell acute lymphoblastic lymphoma occurred in a single 14 year old female patient in an 
extra-oral site, a cervical lymph node.   
 
Lymphoblastic lymphoma (NOS) occurred in a single 12 year old female patient in an oral 
site, the palate. 
 
Acute undifferentiated leukaemia (of ambiguous lineage) occurred in 2 patients and both 
were males.  Age was recorded in both patients.  The median age was 27 years and the age 
range 26 to 28 years.  This subtype occurred in 1 oral site (50%) and 1 extra-oral site 
(50%), and 1 case each (50%) occurred in the buccal mucosa and paranasal sinuses. 
 
5.7 Nodal versus extranodal sites 
Of the 504 head and neck lymphoma cases noted, 137 cases (27%) were of nodal origin 
and 367 cases (73%) were of extranodal origin (Figure 5.5).  Out of the 137 nodal cases,  
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64 patients (46.72%) were male and 73 patients (53.28%) were female.  From the 367 
extranodal cases, 203 patients (55.3%) were male and 163 patients (44.4%) were female 
and one patient had an unknown gender (0.3%).  There was no statistically significant 
difference found in the percentage of males and females in nodal and extranodal sites 
(p=0.1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Percentage comparison of nodal (N) versus extranodal (EN) head and neck 
lymphomas 
 
Of the 137 cases of nodal origin, 89 cases (64.96%) were NHL and 48 cases (35.04 %) 
were HL.  Of the 367 extranodal cases, 364 cases (99.18 %) were NHL and 3 cases 
(0.82%) were HL.  There was a statistically significant difference between the percentage 
of NHL and HL cases of nodal and extranodal origin (p=0.00) 
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5.8 Clinical Features 
The most common clinical presentation was a swelling.  In almost all the cases, the 
neoplasm was described as a swelling/mass or lump.  Ulceration was noted in 57 cases 
(11.31%) of patients and 36 cases (7.14%) complained of pain.  The duration of symptoms 
ranged from 6 days to 10 years.  The nodal lesions ranged in size from 0.3x0.3x0.1cm to 
12x7x6cm while the extranodal lesions ranged in size from 0.3x0.2x0.2cm to 15cm. 
 
5.9 B symptoms   
There was only one patient in this study that had reported B symptoms.  It was a 43 year 
old female with FL of a facial lymph node.  The patient also had hepatosplenomegaly. 
 
5.10 Subtype and gender distribution and age analysis of anatomic sites 
5.10.1 Waldeyer’s ring 
Of the 17 cases that occurred in WR, 10 (58.82%) occurred in the tonsils, 6 (35.29%) in 
the nasopharynx and 1 (5.88%) in the base of the tongue.  10 cases (58.82%) occurred in 
males and 7 (41.18%) in females.  Age was recorded in all 17 patients.  The median age 
was 46 years and the age range was 29 to 92 years.  Of the 17 cases, 14 (82.35%) were 
DLBCL, 2 (11.76%) were FL and 1 (5.88%) was a PBL. 
 
5.10.2 Salivary glands 
Of the 18 cases, 15 cases (83.33%) occurred in the parotid gland and 3 (16.67%) in the 
submandibular gland.  Gender was recorded in 17 patients, 5 (27.78%) males, 12 (66.67%) 
females and one patient had an unknown gender (5.56%).  Age was recorded in all 18 
patients.  The median age was 44.5 years and the age range was 3 to 76 years.  Of the  
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18 cases, 11 (61.11%) were DLBCLs, 4 (22.22%) were MALT lymphomas, 2 (11.11%) 
were PBLs and 1 (5.56%) was a T-cell rich B-cell NHL.   
 
5.10.3 Lymphomas of the jaw 
There were 109 cases which occurred in the jaws, 60 (55.05%) in the maxilla, 42 (38.53%) 
in the mandible and 7 (6.42%) were not otherwise specified.  Of the 109 cases, 64 
(58.72%) patients were male and 45 (41.28%) were female.  Age was recorded in all the 
maxillary cases.  The median age was 41 years and the age range was 5 to 100 years.  Age 
was recorded in 40 of the 42 mandibular cases.  The median age was 36.5 years and the 
age range was 2 to 78 years.  Age was recorded in all 7 of the jaw (NOS) cases.  The 
median age was 28 years and the age range was 6 to 63 years. 
 
5.11 HIV status 
HIV status was recorded in 218 patients (43.25%) of the 504 patients and the HIV status in 
the remaining 286 patients (56.75%) was unknown.  In the 218 patients in which the HIV 
status was known, 199 patients (91.28%) were HIV positive and 19 (8.72%) were HIV 
negative. 
 
5.12 EBV status 
EBV status was recorded in 157 (31.15%) of the 504 cases and the EBV status in the 
remaining 347 (68.85%) patients was unknown.  Of the 157 patients, 61 (38.85%) were 
EBV positive and 96 (61.15%) were EBV negative. 
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5.13 Metastasis, recurrence and second neoplasms 
Metastasis occurred in 12 out of the 504 cases.  Of the 12 patients, 5 had PBLs, 2 had 
DLBCLs, and there was 1 each with SLL, anaplastic large cell lymphoma, peripheral T-
cell lymphoma (NOS), NK/T-cell lymphoma and mixed cellularity CHL. 
 
Recurrence occurred in 5 of the 504 cases.  Two of these patients had FL and 1 each had 
extra-osseous plasmacytoma, mantle cell lymphoma and nodular sclerosing HL.   
 
Of the 504 patients, 4 developed another neoplasm either before or after the lymphomas 
were diagnosed.  Two patients had a history of lip and tonsillar carcinoma and later 
developed PBL and FL respectively.  The third patient had FL of the cervical lymph node 
and later developed keratinising squamous cell carcinoma of the skin.  The last patient had 
DLBCL of the mandible and carcinoma of the cervix. 
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CHAPTER 6 
 
6.0  DISCUSSION 
 
6.1 Frequency over the 20 year period 
As predicted this study showed an overall increase in the number of lymphoma cases 
diagnosed over the 20 year period.  Although this is in keeping with global trends, the 
reasons for the increase in a South African population may differ.  Changes in disease 
patterns, trends and virulence over the past few decades may be contributing factors. 
 
This increasing head and neck lymphoma frequency pattern is in keeping with that of 
literature worldwide (Iguchi et al. 2012, Huh 2012).  The frequency pattern of this study 
was similar to the consistent increase noted in Asia (Korea) with no stabilisation, as well as 
to that of the Western Cape study (Chetty, Sudi & Abayomi 2012) and differed from that 
of the developed countries which have shown some stabilisation in recent years (Huh 
2012). 
 
While reasons such as the AIDS epidemic, improving diagnostic accuracy and reporting, a 
new globally accepted classification system, an aging population and the increase in 
cancer-causing behaviours are all contributing factors, this only accounts for 50% of the 
global increasing trend and most plausible explanations remain unexplained (Huh 2012). 
South Africa is said to have one of the lowest percentages (25%) of HAART coverage in 
HIV patients in the African continent (Brower 2011).  This puts the remaining 75% of the 
AIDS affected patients at a higher risk of acquiring this AIDS-defining cancer.  Chetty, 
Sudi & Abayomi (2012), in their study carried out in the Western Cape, found the 
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commencement of HAART not to have an impact on the lymphoma frequency. They 
attributed these findings to inadequate HAART coverage, delay in starting ART, high viral 
loads and late presentation of disease.  They also considered socio-economic factors such 
as lack of education, poverty, accessibility to healthcare services and female dependence 
on partners to be some of the other contributing factors.  These reasons may also form part 
of the contributing factors in the rise in the number of lymphoma cases found in this study.   
 
Biologic agents that have been associated with the aetiology of malignant lymphomas 
include EBV, HHV8, hepatitis B and C virus, helicobacter pylori, autoimmune disease, 
exposure to certain organic chemicals and pharmaceuticals (Huh 2012).  The current study 
raises the possibility of a link between the increase in the frequency of lymphoma in the 
study cohort and EBV and HIV status. 
 
6.2 Comparison to studies in developed European countries 
Seven reports from the Northern (Finland, United Kingdom), Southern (two from Greece, 
Italy) and Western (Germany, Netherlands) Europe were compared to this study 
(Sӧderholm et al. 1990; Hart et al. 2004; Triantafillidou et al. 2012; Kolokotronis et al. 
2005; Bussu et al. 2013; Scherfler et al. 2012; van der Waal et al. 2005).  Six of the studies 
evaluated NHLs of either the oral cavity only or the head and neck region.  One study 
evaluated both HLs and NHLs of the head and neck region as did the current study. 
 
The aim of most of these studies was to analyse, describe or evaluate the clinical signs and 
symptoms, presenting features and the histological subtypes, in a similar manner to that of 
this study.  The number of cases varied with the largest sample size being 190 patients with 
extranodal lymphomas of the head and neck, over a 30 year period (Hart et al. 2004).  
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These European studies comprised of relatively small sample sizes compared to the 504 
cases in this study.  This is most possibly due to the fact that this study included both HL 
and NHL and was over a larger study period compared to the other studies. 
 
Studies on NHL showed mean ages, ranging from lowest to highest, to be 52; 54.5; 59; 64 
and 64 years (Sӧderholm et al. 1990; Triantafillidou et al. 2012; van der Waal et al. 2005; 
Scherfler et al. 2012; Kolokotronis et al. 2005), with one study reporting a median age of 
65 years (Hart et al. 2004).  The mean age in the head and neck lymphoma study was 59 
years (Bussu et al. 2013). 
 
Our study showed the median age of the NHL cases to be 40 years and the median age of 
the overall head and neck lymphoma cases to be 39 years which is much lower than the 
reported ages noted in the developed European countries.  The lower limit of the ages 
ranged from 1 to 27 years (Scherfler et al. 2012; Kolokotronis et al. 2005) and the upper 
limit ranged from 81 to 93 years (Triantafillidou et al. 2012; Bussu et al. 2013).  This was 
in keeping with the age range of this study which was 2 to 100 years for the NHL cases as 
well as the overall lymphoma age range. 
 
In the developed European countries, three studies showed a slight male predominance 
(van der Waal et al. 2005; Triantafillidou et al. 2012; Bussu et al. 2013) as did this study 
however, three other reports also showed a slight female predominance (Hart et al. 2004; 
Scherfler et al. 2012; Kolokotronis et al. 2005).  Bussu et al. (2013) showed a nodal to 
extranodal ratio of 1:1.94, whilst in the current study a slightly higher ratio of 1:2.7 was 
evident. 
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Six of the European studies found the most common clinical feature to be a swelling/mass  
(Scherfler et al. 2012; Kolokotronis et al. 2005; Triantafillidou et al. 2012; van der Waal et 
al. 2005; Hart et al. 2004; Sӧderholm et al. 1990).  Two reports showed ulceration to be the 
second most common feature (Kolokotronis et al. 2005; van der Waal et al. 2005) while 
one study found pain to be the second most common symptom (Hart et al. 2004).  Two 
studies found dysphagia to be the most common and third most common clinical symptom 
(Bussu et al. 2013; Hart et al. 2004).  The current study recapitulated these findings of a 
swelling or mass to be the most common clinical feature followed by ulceration and pain. 
 
Three studies found the jaw bones and soft tissue of the jaws to be the most common 
anatomic site (Scherfler et al. 2012; Sӧderholm et al. 1990; van der Waal et al. 2005), a 
finding which coincides with that of the current study in which the jaw bones was the most 
common extranodal site.  However, three other reports found the tonsils to be the most 
common extranodal site (Bussu et al. 2013; Hart et al. 2004; Kolokotronis et al. 2005) and 
two studies found this site to be followed by the salivary glands (Bussu et al. 2013; Hart et 
al. 2004). 
 
DLBCL was the commonest subtype in four of the studies (Bussu et al. 2013; Hart et al. 
2004; Kolokotronis et al. 2005; Scherfler et al. 2012) and ranked second to MALT 
lymphoma in a single report (Triantafillidou et al. 2012).  This study found DLBCL to be 
the second most common subtype.  Other common subtypes (in the European studies) 
following DLBCL were MALT, FL and mantle cell lymphoma.  These were the most 
common subtypes, even though the order in which they were ranked in each study varied.  
A similar pattern was not seen in this study. 
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6.3 Comparison to developed North American countries 
Two North American studies one from Boston and the other from Stanford were analysed 
(Kemp et al. 2008; Jacobs & Hoppe 1985).  The one included NHL of the oral cavity only 
and the other included extranodal NHL of the head and neck (Kemp et al. 2008; Jacobs & 
Hoppe 1985).  The study samples were relatively small, 40 and 156 patients respectively 
compared to 453 NHL cases analysed in this study. 
 
Mean ages of 53 and 71 years noted in the two North American studies (Jacobs & Hoppe 
1985; Kemp et al. 2008) were much higher than the median age of 40 years in patients with 
NHL in the present study.  The lower limit of the age ranges was 16 and 35 years 
respectively (Jacobs & Hoppe 1985; Kemp et al. 2008).  Jacobs & Hoppe (1985) excluded 
patients below the age of 16 years in their study, however Kemp et al. (2008) did not state 
any age exclusion and showed a much higher lower age limit (35 years) compared to the 
lower age limit of 2 years noted in the present study.  The upper limit of the age range in 
patients with NHL in this study was 100 years, which was higher than the 81 and 89 years 
found in the North American studies (Jacobs & Hoppe 1985; Kemp et al. 2008).  Similar to 
the current study, Jacobs & Hoppe (1985) found a slight male predominance whilst Kemp 
et al. (2008) found a slight female predominance. 
 
Like the present study, Kemp et al. (2008) found swelling and ulceration to be the most 
common clinical features.  Jacobs & Hoppe (1985) reported 12% of patients with B 
symptoms which differed from this study, in which only 1 patient (0.2%) showed B 
symptoms.  In both this study and that of Kemp et al. (2008), the jaw bones followed by 
the palate were the most common anatomic sites, whilst in the study by Jacobs & Hoppe 
(1985) WR followed by the salivary glands were the most common sites. 
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The B-cell to NK/T-cell ratio found in the study by Kemp et al. (2008) (49:1) was far 
higher than that found in this study (11.88:1).  The most common subtype in their study 
was DLBCL followed by FL, extranodal marginal zone lymphoma and plasma cell 
tumours while this study found PBL to be the most common subtype followed by DLBCL, 
BL and plasma cell tumours, when considering only the NHLs. 
 
6.4 Comparison to developed Middle East and Asian countries 
Reports from Iran, Israel and Japan that were analysed and compared to the findings of this 
study, included a study on NHL of the head and neck, a study on oral and pharyngeal 
lymphoma and one of lymphoid neoplasms of the head and neck (Etemad-Moghadam et al. 
2010; Zini et al. 2012; Iguchi et al. 2012).  The incidence rate of lymphomas noted in each 
study was 0.48%, 5.7% and 15.1% respectively.  
 
The mean age of the head and neck NHL study was 46.3 years which was slightly higher 
than the median age (40 years) of the NHL cases in this study (Etemad-Moghadam et al. 
2010).  The two lymphoma studies reported mean and median ages of 59.5 years and 66 
years respectively (Zini et al. 2012; Iguchi et al. 2012) which were far higher than the 
median age of 39 years in this study.  The age ranges of the Iranian (7 months - 98 years) 
and the Israeli study (2- 97 years) were very similar to that of this study (2- 100 years) 
however, it differed from the Japanese study (17- 89 years) which had a much higher lower 
age limit and a slightly lower upper age limit (Etemad-Moghadam et al. 2010; Zini et al. 
2012; Iguchi et al. 2012).  The M:F ratio of this study (1.13:1) was almost the same as that 
of the Israeli study (1.1:1) however, the ratio was much lower than the Iranian (2.2:1) and 
Japanese (2.3:1) studies (Zini et al. 2012; Etemad-Moghadam et al. 2010; Iguchi et al. 
2012). 
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The nodal to extranodal ratio found in the Iranian study (1:0.36) was lower than that found 
in this study (1:2.7) (Etemad-Moghadam et al. 2010).  The HL to NHL ratio of the Israeli 
(1:25) and Japanese studies (1:29) was far higher than that found in this study (1:9).  The 
B-cell to NK/T-cell lymphoma ratio of 11.88:1 in this study was higher than that of the 
Japanese study (4.3:1) and much lower than that of the Israeli study (48.5:1) (Iguchi et al. 
2012; Zini et al. 2012). 
 
As seen in the present study, the most common clinical feature recorded in the Iranian 
population was a local mass (Etemad-Moghadam et al. 2010).  WR was found to be the 
most common anatomic site in all three studies accounting for 36%, 36% and 67.5% of 
cases (Etemad-Moghadam et al. 2010; Zini et al. 2012; Iguchi et al. 2012).  This differed 
from the present study that found cervical lymph nodes to be the most common overall 
anatomic site and the maxilla to be the most common extranodal site.  WR only accounted 
for 17% of cases in this study. 
 
PBL (31.55%) was the most common histological subtype followed by DLBCL (30.75%) 
in this study, whilst DLBCL was the most common histological subtype in the Iranian 
(65%) and Japanese (54.9%) populations (Etemad-Moghadam et al. 2010; Iguchi et al. 
2012). 
 
6.5 Comparison to a developing Asian country 
A retrospective study on primary NHLs of the oral cavity in South India over an 
approximate 10 year period showed only seven cases of NHLs compared to the 453 NHL 
cases found in this 20 year retrospective study (Sirsath et al. 2014).  Similar to this study 
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which showed a median age of 40 years in patients with NHL, the median age was 43.2 
years.  The ages ranged from 29 to 65 years compared to 2 to 100 years found in this study.  
The lower age limit of their study (29 years) was much higher than that in this study  
(2 years) and the upper age limit (65 years) was much lower than that of this study  
(100 years).  Similar to our study, a slight male predominance was noted in their study. 
 
Like the present study, all patients in the South Indian study presented with a slow growing 
ulcerative mass (Sirsath et al. 2014).  Similarly no patients showed B symptoms in their 
study compared to the single patient in our study with B symptoms.  The most common 
anatomic site in their study was the anterior two-thirds of the tongue which differed from 
our study, in which the maxilla was the most common oral site. 
 
Comparable to the current study, the study by Sirsath et al. (2014) found the most common 
histological subtypes to be PBL followed by DLBCL.  Unlike their study that found 
peripheral T-cell lymphoma (NOS) to be the third most common NHL, this lymphoma 
ranked fifth in our study. 
 
6.6 Comparison to a South African study 
Similar to our study (Gauteng Province, South Africa) a 5 year retrospective study (2003- 
2007) on head and neck lymphomas was carried out in a South African population in the 
Western Cape (Chetty, Sudi & Abayomi 2012).  The total number of lymphoma cases in 
this study was 242.  The M:F ratio of 1.08:1 found in the Western Cape study was similar 
to the 1.13:1 found in the present study. 
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The nodal to extranodal lymphoma ratio in this study was 1:2.7 compared to their 1:0.58.  
The HL to NHL ratio of this study (1:9) was much higher than that of their study (1: 2.57).  
DLBCL ranked first in the Western Cape study and second in this study however the 
frequency of DLBCL in both studies was similar; namely 30.75% in this study and 32% in 
the Western Cape.  There were 23.55% more PBLs in the present study compared to the 
Western Cape study, whilst their study found 17% more HLs and 8.02% more FLs than 
this study. 
 
Whilst the cervical lymph nodes were the most common site in both the studies, this was 
much higher in the Western Cape study (64%) compared to our study (22.82%).  Oral sites 
accounted for 25% of cases in the Western Cape compared to 57% in this study.  Salivary 
gland lymphomas accounted for 3.57% of cases in this study and this was slightly lower 
than their 5% of cases. 
 
HIV status was known in 43.25% of cases in this study compared to 80% of known HIV 
cases in the Western Cape.  Our study found slightly more HIV positive cases (39.48%) 
than the Western Cape study (35%), whilst they showed more HIV negative cases (45%) 
compared to the negative cases (3.77%) in our study.  This is however probably due to the 
fact that the number of patients with a known HIV status was almost double when 
compared to our cohort of patients with known HIV status. 
 
  
73 
 
6.7 Study limitations and strengths 
Chiu & Weisenburger (2003) attributed only a third of the lymphoma increase to the 
possible causative factors with the reasons for the increase in the remaining two-thirds of 
cases to be unknown.  Their reasoning however is not based on African nor especially 
South African statistics, where the incidence rates of HIV and AIDS continue to be the 
highest in the world (Granich et al. 2015).  Whilst the Western Cape study confirmed an 
association between the HIV epidemic and increase in the frequency of the head and neck 
lymphoma, the probable relationship between HIV and AIDS as a reason for the increase 
of NHL noted in this study cannot be confirmed due to the unknown HIV status of a large 
number of patients in the cohort analysed.   
 
This lack of information proved to be a limitation of the study as regards drawing any 
association between HIV and AIDS and head and neck lymphomas.  This information as 
well as data regarding CD4 count and viral load is mandatory for future studies of this 
nature.  A further limitation noted was the under reporting of cases due to various reasons, 
compromising adequate data collection and rendering the data not a true representation of 
the larger population.  Technical and non-technical bias may also pose as a limitation to 
this study.   
 
Furthermore, information regarding HIV and EBV status as well as whether the tumour 
was part of a generalised multifocal process or a primary tumour was not always available 
resulting in incomplete data.  Also as a result of modern diagnostic aids such as 
immunohistochemistry and molecular diagnostic techniques, as well as more recent 
classification systems, there is a possibility that some of the earlier reported diagnoses may 
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have been inaccurate or incorrect, and may have changed with the adjunctive use of 
immunohistochemistry and molecular diagnostic techniques.   
 
It is important to note that this study is only a description of the frequency of lymphomas 
diagnosed in a defined Oral Pathology Unit.  In this regard the study does not represent a 
true reflection of the frequency of the various head and neck lymphoma subtypes seen by 
pathologists in the greater Johannesburg area. 
 
This study included both HL and NHL with the aim of having a general overview of the 
lymphomas occurring in the head and neck region and more specifically the oral cavity.  
Perhaps inclusion of only B-cell non-Hodgkin’s lymphomas in the study would have 
rendered the study more focussed. 
 
A major strength of this 20 year retrospective study is that it offers an overview of the head 
and neck lymphomas seen in a defined population sample in South Africa.  Furthermore, it 
provides a baseline or reference for future head and neck lymphoma studies to be carried 
out, especially in South Africa.   
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CHAPTER 7 
 
7.0  CONCLUSION 
 
This study confirmed the increase in head and neck lymphoma frequency over the 20 year 
period found in a defined South African population within the Department of Oral 
Pathology, University of the Witwatersrand, Johannesburg.  A finding which is contrary to 
that found in Western countries, which have shown a decline in the lymphoma frequency 
with the advent of HAART. 
 
Head and neck lymphomas represent 2.24% of the total number of oral pathology cases 
diagnosed in the Department of Oral Pathology; 90% of the total number of lymphomas 
being NHL and 10% HL.  PBL, DLBCL and BL represent the three most common 
histological subtypes.  The reason for the strong predilection of PBL for the oral cavity 
remains unknown. 
 
Lymphomas of the oral and maxillofacial region occurred over a wide age range with 
predominance for the third decade and a strong male bias.  Even though the male to female 
ratio and age range differed in each subtype; most lymphomas occurred in males and 
ranged in age from 2 to100 years (median, 39 years). 
 
Head and neck lymphomas are predominantly extranodal (73%), usually presenting as 
ulcerated painful swellings.  The most common anatomic site was the cervical lymph node, 
with the maxilla being the most common extranodal site. 
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The high prevalence of HIV in certain lymphoma categories provides a strong indication, 
all be it circumstantial evidence of the pivotal role of HIV and AIDS in the pathogenesis of 
this lymphomas, especially PBL, DLBCL and BL.  Further research elucidating the 
molecular oncogenic pathway of both HIV and EBV is recommended. 
 
Future studies should include long term prospective analyses on NHL patients with a strict 
ART regime on early and late diagnosed HIV and AIDS patients in order to monitor and 
evaluate the effect of a strict ART regime on the incidence of AIDS-related cancers.  This 
would provide a major breakthrough in the study of lymphomas in the HIV and AIDS era.  
Such findings could motivate healthcare workers and patients in ensuring compliance with 
ART as well as ensuring government and non-governmental organisations to assist in 
providing services in the heart of communities and rural areas in order to reduce the 
morbidity and mortality associated with AIDS-related cancers.   
 
Further investigation into the aetiological factors of lymphomas, with emphasis on risk 
factors, lifestyle and medical history is needed (Zini et al. 2012).  Insight on the causative 
factors of the disease will contribute in reducing the annual number of fatalities caused by 
this neoplasm. 
 
Furthermore, in view of the increasing lymphoma incidence there is a need for a uniform 
reporting system in order to establish accurate epidemiologic comparisons in different 
populations and countries.  This will provide an improved prognostication of oral and 
maxillofacial lymphomas and will be most valuable for both clinicians and pathologists. 
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CHAPTER 9 
9.0  APPENDICES 
9.1 APPENDIX 1: DATA COLLECTION SHEET 
Head and neck lymphomas: a 20 year retrospective review of cases diagnosed in an Oral Pathology 
Unit, Johannesburg, South Africa 
Pathology report no.   Date D D M M Y Y 
          
 
Age   Gender Male Female  
 
 
  
Lymphoma-Histological Type/Subtype:  
Hodgkin   
          Subtype   
Non-Hodgkin   
B cell   
          Subtype   
      T cell   
          Subtype   
Additional information:   
Clinical appearance: 
_______________________________________________________________________________________ 
Anatomic Site 
Size Nodal/ 
Extranodal 
lymphoma 
Metastatic/ 
Primary/ 
Second/ 
unknown site 
Presence of 
Systemic disease: 
e.gbone marrow 
involvement 
 
    
Gingiva     
Palate     
Tongue     
Buccal mucosa     
Tonsils     
Pharynx     
Maxillary Sinus     
Salivary glands     
Parotid gland     
Submandibular gland     
Sublingual gland     
Nasopharynx     
Cervical lymph node     
Other:     
 
Local RG findings: __________________________________________________________ 
Systemic RG findings: _______________________________________________________ 
Additional General information: 
___________________________________________________________________________ 
HIV Status Positive Negative EBV Status 
Positive Negative 
Type of  
test 
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9.2 APPENDIX 2: WHO CLASSIFICATION OF LYMPHOID NEOPLASMS 
ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE 
 Acute undifferentiated leukaemia 
 Mixed phenotype acute leukaemia with t(9;22)(q34;q11.2); BCR-ABL1 
 Mixed phenotype acute leukaemia with t(v;11q23); MLL rearranged 
 Mixed phenotype acute leukaemia, B/myeloid, NOS 
 Mixed phenotype acute leukaemia, T/myeloid, NOS 
 Natural killer (NK) cell lymphoblastic leukaemia/lymphoma 
 
PRECURSOR LYMPHOID NEOPLASMS 
B lymphoblastic leukaemia/lymphoma 
 B lymphoblastic leukaemia/lymphoma, NOS 
 B lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities 
 B lymphoblastic leukaemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1 
 B lymphoblastic leukaemia/lymphoma with t(v;11q23) MLL rearranged 
 B lymphoblastic leukaemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) 
 B lymphoblastic leukaemia/lymphoma with hyperdiploidy 
 B lymphoblastic leukaemia/lymphoma with hypodiploidy (hypodiploid ALL) 
 B lymphoblastic leukaemia/lymphoma, NOS 
 B lymphoblastic leukaemia/lymphoma with t(5;14)(q31;q32); IL3-IGH 
 B lymphoblastic leukaemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) 
T lymphoblastic leukaemia/lymphoma 
 
MATURE B-CELL NEOPLASMS 
 Chronic lymphocytic leukaemia/small lymphocytic lymphoma 
 B-cell prolymphocytic leukaemia 
 Splenic B-cell marginal zone lymphoma 
 Hairy cell leukaemia 
 Splenic B-cell lymphoma/leukaemia, unclassifiable 
 Splenic diffuse red pulp small B-cell lymphoma 
 Hairy cell leukaemia-variant 
 Lymphoplasmacytic lymphoma 
 Waldenstrӧmmacroglobulinemia 
 Heavy chain diseases 
 Alpha heavy chain disease 
 Gamma heavy chain disease 
 Mu heavy chain disease 
 
 Plasma cell myeloma 
 Solitary plasmacytoma of bone 
 Extraosseousplasmacytoma 
 Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) 
 Nodal marginal zone lymphoma 
 Paediatric nodal marginal zone lymphoma 
 
 Follicular lymphoma 
 Paediatric follicular lymphoma 
 
 Primary cutaneous follicle centre lymphoma 
 Mantle cell lymphoma 
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 Diffuse large B-cell lymphoma (DLBCL),NOS 
 T-cell/histiocyte rich large B-cell lymphoma 
 Primary DLBCL of the CNS 
 Primary cutaneous DLBCL, leg type 
 EBV positive DLBCL of the elderly 
 DLBCL associated with chronic inflammation 
 Lymphomatoidgranulomatosis 
 Primary mediastinal (thymic) large B-cell lymphoma 
 Intravascular large B-cell lymphoma 
 ALK positive large B-cell lymphoma 
 Plasmablastic lymphoma 
 Large B-cell lymphoma arising in HHV8- associated multicentricCastleman disease 
 Primary effusion lymphoma 
 Burkitt lymphoma 
 B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and 
Burkitt lymphoma 
 B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and 
classical Hodgkin lymphoma 
 
MATURE T-CELL AND NK-CELL NEOPLASMS 
 T-cell prolymphocytic leukaemia 
 T-cell large granular lymphocytic leukaemia 
 Chronic lymphoproliferative disorder of NK-cells 
 Aggressive NK cell leukaemia 
 Systemic EBV positive T-cell lymphoproliferative disease of childhood 
 Hydroavacciniforme-like lymphoma 
 Adult T-cell leukaemia/lymphoma 
 Extranodal NK/T cell lymphoma, nasal type 
 Enteropathy-associated T-cell lymphoma 
 Hepatosplenic T-cell lymphoma 
 Subcutaneous panniculitis-like T-cell lymphoma 
 Mycosis fungoides 
 Sézary syndrome 
 Primary cutaneous CD30 positive T-cell lymphoproliferative disorders 
 Lympomatoidpapulosis 
 Primary cutaneous anaplastic large cell lymphoma 
 Primary cutaneous gamma-delta T-cell lymphoma 
 Primary cutaneous CD8 positive aggressive epidermotropic cytotoxic T-cell lymphoma 
 Primary cutaneous CD4 positive small/medium T-cell lymphoma 
 Peripheral T-cell lymphoma, NOS 
 Angioimmunoblastic T-cell lymphoma 
 Anaplastic large cell lymphoma, ALK positive 
 Anaplastic large cell lymphoma, ALK negative 
 
HODGKIN LYMPHOMA 
 Nodular lymphocyte predominant Hodgkin lymphoma 
 Classical Hodgkin lymphoma 
 Nodular sclerosis classical Hodgkin lymphoma 
 Lymphocyte –rich classical Hodgkin lymphoma 
 Mixed cellularity classical Hodgkin lymphoma 
 Lymphocyte-depleted classical Hodgkin lymphoma 
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9.4 APPENDIX 4: Turnitin Report  
 
Turnitin Originality Report  
SMNasDraft42DEC2015forturnitin1.docx by Null Null  
From Head and Neck Lymphomas: A 20 year Retrospective Review of Cases Diagnosed in an 
Oral Pathology Unit 
(DQG777S1VT73YFL8sWnN42b0u524qhbznX9jotxSkoCF8FiWNi0FK9Dy9LN0n2yAhYnxx6U
1ULdYCkMk689qXpro4pl93TWG8yK)  
 Processed on 03-Dec-2015 9:36 AM SAST  
 ID: 609133383  
 Word Count: 19412  
  
Similarity Index 
10% 
Similarity by Source 
Internet Sources:  
4%  
Publications:  
9%  
Student Papers:  
1%  
sources: 
1 
1% match (publications) 
Vega, F.. "Extranodal lymphomas of the head and neck", Annals of Diagnostic Pathology, 
200512  
2 
< 1% match (publications) 
Pei Lin. "Hematopoietic Lesions", Diagnostic Surgical Pathology of the Head and Neck, 2009  
3 
< 1% match (Internet from 20-Aug-2014) 
http://wiredspace.rcpsych.org/  
4 
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9.6 APPENDIX 6: Raw data 
Year Patient Age Gender Subtype HL/
NHL
N/
EN
Site O /
EO
2012 1 12 M NS CHL HL N cervical LN EO
2012 2 27 F NLP HL HL N cervical LN EO
2012 3 34 M DLBCL NHL EN palate O
2012 4 38 F DLBCL NHL N cervical LN EO
2012 5 47 F NS CHL HL N cervical LN EO
2012 6 32 F PBL NHL EN buccal mucosa O
2012 7 32 F PBL NHL EN maxilla O
2012 8 42 M PBL NHL EN Floor of mouth O
2012 9 28 M MC CHL HL N cervical LN EO
2012 10 44 M DLBCL NHL EN Salivary gland EO
2012 11 47 F NS CHL HL N cervical LN EO
2012 12 40 M PBL NHL EN buccal mucosa O
2012 13 75 M DLBCL NHL N cervical LN EO
2012 14 46 M DLBCL NHL EN WR O
2012 15 38 F PBL NHL EN buccal mucosa O
2012 16 59 F Burkitt-like lymphoma NHL EN orbit EO
2012 17 30 M DLBCL NHL EN neck EO
2012 18 40 F DLBCL NHL EN WR O
2012 19 29 F Peripheral T-cell lymphoma (NOS) NHL EN neck EO
2012 20 54 M PBL NHL EN lip O
2012 21 27 F NS CHL HL N cervical LN EO
2012 22 28 F NS CHL HL N cervical LN EO
2012 23 43 M DLBCL NHL EN posterior nasal space EO
2012 24 42 M PBL NHL EN mandible O
2012 25 47 F NS CHL HL N cervical LN EO
2012 26 41 M NK/T-cell lymphoma (nasal type) NHL EN nasal cavity EO
2012 27 36 M DLBCL NHL EN gingiva O
2012 28 46 M PBL NHL EN buccal mucosa O
2012 29 38 F DLBCL NHL N max-facial LN EO
2012 30 68 M Plasma cell myeloma NHL EN Paranasal sinuses EO
2012 31 29 M NLP HL HL N cervical LN EO
2012 32 36 M DLBCL NHL EN neck EO
2012 33 41 M PBL NHL EN maxilla O
2012 34 32 M PBL NHL EN nasal cavity EO
2012 35 41 M PBL NHL EN maxilla O
2012 36 36 M FL NHL EN WR O
2012 37 25 F NLP HL HL N cervical LN EO
2012 38 15 F NS CHL HL N cervical LN EO
2012 39 48 M PBL NHL EN Buccal vestibule O
2012 40 21 F NS CHL HL N cervical LN EO
2012 41 37 M Anaplastic large cell lymphoma NHL N cervical LN EO
2012 42 25 M DLBCL NHL N cervical LN EO
2012 43 30 M DLBCL NHL N cervical LN EO
2012 44 42 M PBL NHL EN Oral cavity (NOS) O
2012 45 34 F MC CHL HL EN neck EO
2012 46 22 F PBL NHL EN Pharynx EO
2012 47 33 F BL NHL EN mandible O
2012 48 41 M PBL NHL EN palate O
2012 49 57 M DLBCL NHL EN WR O
2012 50 45 F PBL NHL EN palate O  
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2012 51 76 F PBL NHL EN Salivary gland EO
2012 52 28 F BL NHL EN mandible O
2012 53 51 F NLP HL HL N cervical LN EO
2012 54 64 M DLBCL NHL EN WR O
2012 55 37 M PBL NHL EN mandible O
2012 56 52 M DLBCL NHL EN WR O
2012 57 38 M DLBCL NHL N cervical LN EO
2012 58 43 F FL NHL N max-facial LN EO
2011 59 32 F PBL NHL EN maxilla O
2011 60 39 F MC CHL HL N cervical LN EO
2011 61 56 M PBL NHL EN maxilla O
2011 62 38 M PBL NHL EN maxilla O
2011 63 17 M MC CHL HL N cervical LN EO
2011 64 51 M DLBCL NHL N cervical LN EO
2011 65 27 F PBL NHL EN maxilla O
2011 66 45 F MC CHL HL N cervical LN O
2011 67 40 M PBL NHL EN palate O
2011 68 40 M PBL NHL EN mandible O
2011 69 38 F PBL NHL EN palate O
2011 70 31 F PBL NHL EN Alveolus O
2011 71 32 M MC CHL HL N cervical LN EO
2011 72 29 M NK/T-cell lymphoma (nasal type) NHL EN Paranasal sinuses EO
2011 73 62 M SLL NHL N cervical LN EO
2011 74 18 M NS CHL HL N cervical LN EO
2011 75 31 F PBL NHL EN palate O
2011 76 33 F NK/T-cell lymphoma (nasal type) NHL EN maxilla O
2011 77 14 F NS CHL HL N cervical LN EO
2011 78 34 F DLBCL NHL N cervical LN EO
2011 79 27 F PBL NHL EN palate O
2011 80 18 M NLP HL HL N cervical LN EO
2011 81 39 M NS CHL HL N cervical LN EO
2011 82 40 F PBL NHL N max-facial LN EO
2011 83 22 F DLBCL NHL N cervical LN EO
2011 84 33 F DLBCL NHL N cervical LN EO
2011 85 33 M PBL NHL EN posterior nasal space EO
2011 86 42 F DLBCL NHL N max-facial LN EO
2011 87 45 M DLBCL NHL EN buccal mucosa O
2011 88 31 F DLBCL NHL EN WR O
2011 89 67 M Mantle cell lymphoma NHL N cervical LN EO
2011 90 29 M DLBCL NHL EN Jaw (NOS) O
2011 91 40 F DLBCL NHL N cervical LN EO
2011 92 32 M NK/T-cel lymphoma (nasal type) NHL EN palate O
2011 93 59 M PBL NHL EN maxilla O
2011 94 42 M PBL NHL EN palate O
2011 95 40 M DLBCL NHL EN Paranasal sinuses EO
2011 96 41 F DLBCL NHL EN Posterior nasal space EO
2011 97 42 F PBL NHL EN maxilla O
2011 98 57 M DLBCL NHL EN mandible O
2011 99 30 M NLP HL HL N cervical LN EO
2011 100 31 M DLBCL NHL EN nasal cavity EO
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2011 101 26 F PBL NHL EN maxilla O
2011 102 92 M DLBCL NHL EN WR O
2011 103 36 F PBL NHL EN maxilla O
2011 104 77 F SLL NHL N max-facial LN EO
2011 105 34 F DLBCL NHL EN WR O
2011 106 38 M DLBCL NHL EN nasal cavity EO
2011 107 37 M PBL NHL EN Floor of mouth O
2011 108 41 M PBL NHL EN gingiva O
2011 109 38 M FL NHL N cervical LN EO
2011 110 40 M PBL NHL EN palate O
2011 111 60 M SLL NHL N cervical LN EO
2011 112 37 F DLBCL NHL EN Salivary gland EO
2011 113 24 M Anaplastic large cell lymphoma NHL N cervical LN EO
2011 114 28 M PBL NHL EN palate O
2011 115 38 M DLBCL NHL N cervical LN EO
2011 116 31 F BL NHL N cervical LN EO
2011 117 31 F BL NHL EN Oral cavity (NOS) O
2011 118 40 F DLBCL NHL N cervical LN EO
2011 119 32 M NS CHL HL N cervical LN EO
2011 120 61 F NK/T-cell lymphoma (nasal type) NHL EN nasal cavity EO
2010 121 46 M PBL NHL EN maxilla O
2010 122 50 F DLBCL NHL N cervical LN EO
2010 123 42 M Extraosseous plasmacytoma NHL EN maxilla O
2010 124 27 M BL NHL N cervical LN EO
2010 125 24 M DLBCL NHL N cervical LN EO
2010 126 16 F Anaplastic large cell lymphoma NHL EN neck EO
2010 127 45 F DLBCL NHL N cervical LN EO
2010 128 10 M Anaplastic large cell lymphoma NHL N cervical LN EO
2010 129 36 M MC CHL HL N cervical LN EO
2010 130 47 M NS CHL HL N cervical LN EO
2010 131 49 M DLBCL NHL EN mandible O
2010 132 27 F DLBCL NHL N cervical LN EO
2010 133 12 F PBL NHL N cervical LN EO
2010 134 43 M PBL NHL EN maxilla O
2010 135 57 M Mantle cell lymphoma NHL EN buccal mucosa O
2010 136 33 F DLBCL NHL EN WR O
2010 137 31 M DLBCL NHL N cervical LN EO
2010 138 56 F DLBCL NHL EN Tonsillar fossa area O
2010 139 56 M SLL NHL N cervical LN EO
2010 140 28 F Peripheral T -cell lymphoma (NOS) NHL EN Submental area EO
2010 141 36 M PBL NHL EN maxilla O
2010 142 35 M DLBCL NHL N max-facial LN EO
2010 143 31 M DLBCL NHL N cervical LN EO
2010 144 70 M DLBCL NHL EN WR O
2010 145 46 M Solitary plasmacytoma of bone NHL EN maxilla O
2010 146 56 M DLBCL NHL EN WR O
2010 147 43 F DLBCL NHL EN Buccal vestibule O
2010 148 37 M Peripheral T -cell lymphoma (NOS) NHL EN palate O
2010 149 46 M PBL NHL EN buccal mucosa O
2010 150 31 M PBL NHL EN Buccal vestibule O
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2010 151 48 M DLBCL NHL EN Buccal vestibule O
2010 152 40 F DLBCL NHL N cervical LN EO
2010 153 47 M Plasma cell myeloma NHL EN Scalp EO
2010 154 84 F DLBCL NHL N max-facial LN EO
2010 155 22 F DLBCL NHL N cervical LN EO
2010 156 57 M PBL NHL EN nasal cavity EO
2010 157 55 F PBL NHL EN mandible O
2010 158 46 M PBL NHL EN nasal cavity EO
2010 159 18 M NLP HL HL N max-facial LN EO
2010 160 29 M PBL NHL EN mandible O
2010 161 26 F DLBCL NHL EN gingiva O
2010 162 42 F DLBCL NHL EN gingiva O
2010 163 41 M PBL NHL EN Salivary gland EO
2010 164 31 M PBL NHL EN mandible O
2010 165 35 M PBL NHL EN mandible O
2010 166 48 M FL NHL N cervical LN EO
2010 167 9 F DLBCL NHL N cervical LN EO
2010 168 26 M PBL NHL EN palate O
2010 169 17 M MC CHL HL N cervical LN EO
2010 170 26 F BL NHL EN buccal mucosa O
2010 171 48 M PBL NHL EN gingiva O
2010 172 36 F DLBCL NHL EN mandible O
2010 173 50 M DLBCL NHL N max-facial LN EO
2010 174 41 M PBL NHL EN maxilla O
2010 175 65 M Plasma cell myeloma NHL EN nasal cavity EO
2010 176 45 F DLBCL NHL EN Salivary gland EO
2009 177 26 F PBL NHL EN gingiva O
2009 178 46 F DLBCL NHL EN WR O
2009 179 44 M DLBCL NHL EN Floor of mouth O
2009 180 48 M PBL NHL EN maxilla O
2009 181 30 M DLBCL NHL EN mandible O
2009 182 28 F PBL NHL EN gingiva O
2009 183 44 M DLBCL NHL EN Face EO
2009 184 31 F PBL NHL EN Posterior nasal space EO
2009 185 38 M DLBCL NHL N cervical LN EO
2009 186 42 M DLBCL NHL N cervical LN EO
2009 187 39 M PBL NHL EN mandible O
2009 188 29 F DLBCL NHL EN palate O
2009 189 33 F PBL NHL EN palate O
2009 190 45 M PBL NHL EN maxilla O
2009 191 43 F DLBCL NHL N cervical LN EO
2009 192 30 F PBL NHL EN buccal mucosa O
2009 193 46 F DLBCL NHL EN Buccal vestibule O
2009 194 44 M PBL NHL EN gingiva O
2009 195 37 F DLBCL NHL N cervical LN EO
2009 196 29 M DLBCL NHL EN WR O
2009 197 30 F PBL NHL N cervical LN EO
2009 198 27 F DLBCL NHL N cervical LN EO
2009 199 34 F DLBCL NHL EN nasal cavity EO
2009 200 50 M PBL NHL EN buccal mucosa O  
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2009 201 33 F DLBCL NHL EN neck EO
2009 202 37 M PBL NHL EN gingiva O
2009 203 45 M DLBCL NHL EN maxilla O
2009 204 34 F DLBCL NHL EN WR O
2009 205 44 M DLBCL NHL EN neck EO
2009 206 43 F PBL NHL EN nasal cavity EO
2009 207 45 F DLBCL NHL EN Posterior nasal space EO
2009 208 59 F Plasma cell myeloma NHL EN maxilla O
2009 209 56 F DLBCL NHL EN Larynx EO
2009 210 39 F PBL NHL EN mandible O
2009 211 50 M DLBCL NHL N cervical LN EO
2009 212 57 M DLBCL NHL N cervical LN EO
2009 213 30 F DLBCL NHL EN Oropharynx O
2009 214 33 F DLBCL NHL N cervical LN EO
2009 215 46 M PBL NHL EN gingiva O
2009 216 36 M PBL NHL EN WR O
2009 217 77 M Plasma cell myeloma NHL EN maxilla O
2009 218 84 M PBL NHL EN nasal cavity EO
2009 219 43 M PBL NHL EN gingiva O
2009 220 48 F Extraosseous plasmacytoma NHL EN gingiva O
2009 221 30 F BL NHL EN mandible O
2009 222 41 M Mantle cell lymphoma NHL EN Posterior nasal space EO
2009 223 88 F Marginal zone lymphoma NHL N cervical LN EO
2009 224 31 F NS CHL HL N cervical LN EO
2009 225 38 M NS CHL HL N cervical LN EO
2009 226 6 M BL NHL EN Paranasal sinuses EO
2009 227 33 F NS CHL HL N cervical LN EO
2009 228 14 F T-cell acute lymphoblastic 
lymphoma
NHL N cervical LN EO
2009 229 4 M Anaplastic large cell lymphoma NHL EN Floor of mouth O
2009 230 36 F BL NHL EN Posterior nasal space EO
2009 231 11 M Peripheral T -cell lymphoma (NOS) NHL EN maxilla O
2009 232 38 M DLBCL NHL N cervical LN EO
2009 233 19 M NLP HL HL N max-facial LN EO
2009 234 34 M DLBCL NHL N cervical LN EO
2009 235 33 F NS CHL HL N cervical LN EO
2009 236 34 F Anaplastic large cell lymphoma NHL EN maxilla O
2009 237 42 M Extraosseous plasmacytoma NHL EN nasal cavity EO
2009 238 60 M MALT lymphoma NHL EN buccal mucosa O
2008 239 35 M PBL NHL EN mandible O
2008 240 39 M PBL NHL EN buccal mucosa O
2008 241 17 F DLBCL NHL EN Salivary gland EO
2008 242 41 F PBL NHL EN palate O
2008 243 51 M PBL NHL EN buccal mucosa O
2008 244 53 F Plasma cell myeloma NHL EN mandible O
2008 245 61 F DLBCL NHL EN neck EO
2008 246 41 F PBL NHL EN palate O
2008 247 35 M PBL NHL EN palate O
2008 248 36 M PBL NHL EN gingiva O
2008 249 51 M PBL NHL EN Oral cavity (NOS) O
2008 250 58 M PBL NHL EN Face EO
2008 251 33 F DLBCL NHL EN Salivary gland EO
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2008 252 37 F DLBCL NHL EN Submandibular area EO
2008 253 38 M PBL NHL EN Posterior nasal space EO
2008 254 44 M PBL NHL EN Posterior nasal space EO
2008 255 43 F DLBCL NHL EN Pharynx EO
2008 256 42 F PBL NHL EN buccal mucosa O
2008 257 11 F PBL NHL N cervical LN EO
2008 258 32 M PBL NHL EN maxilla O
2008 259 42 M PBL NHL EN gingiva O
2008 260 43 F Atypical BL NHL EN maxilla O
2008 261 60 F MALT lymphoma NHL EN Salivary gland EO
2008 262 52 F Plasma cell myeloma NHL EN maxilla O
2008 263 41 M NK/T-cell lymphoma (nasal type) NHL EN Face EO
2008 264 25 F MC CHL HL EN buccal mucosa O
2008 265 41 F NS CHL HL N cervical LN EO
2008 266 44 M PBL NHL EN gingiva O
2008 267 50 F Plasma cell myeloma NHL EN mandible O
2008 268 38 F Plasma cell myeloma NHL EN mandible O
2008 269 24 F SLL NHL EN Parapharynx EO
2008 270 55 F Peripheral T -cell lymphoma (NOS) NHL EN nasal cavity EO
2008 271 60 M PBL NHL EN Larynx EO
2008 272 44 F Atypical BL NHL EN buccal mucosa O
2008 273 36 F NK/T-cell lymphoma (nasal type) NHL EN nasal cavity EO
2008 274 19 M Anaplastic large cell lymphoma NHL EN buccal mucosa O
2008 275 66 F Plasma cell myeloma NHL EN gingiva O
2008 276 50 F Peripheral T -cell lymphoma (NOS) NHL N cervical LN EO
2007 277 60 M PBL NHL EN Paranasal sinuses EO
2007 278 45 F DLBCL NHL N max-facial LN EO
2007 279 35 M PBL NHL EN gingiva O
2007 280 50 M PBL NHL EN Floor of mouth O
2007 281 32 M DLBCL NHL EN buccal mucosa O
2007 282 40 F DLBCL NHL N cervical LN EO
2007 283 54 M PBL NHL EN Buccal vestibule O
2007 284 42 M DLBCL NHL EN Salivary gland EO
2007 285 41 M DLBCL NHL N max-facial LN EO
2007 286 20 M PBL NHL EN Paranasal sinuses EO
2007 287 38 M PBL NHL EN gingiva O
2007 288 63 F DLBCL NHL EN Tongue O
2007 289 27 F PBL NHL EN mandible O
2007 290 29 M DLBCL NHL EN gingiva O
2007 291 46 F DLBCL NHL N max-facial LN EO
2007 292 39 F PBL NHL EN Paranasal sinuses EO
2007 293 23 F DLBCL NHL EN palate O
2007 294 58 M PBL NHL EN palate O
2007 295 38 M PBL NHL EN Paranasal sinuses EO
2007 296 60 F Plasma cell myeloma NHL EN maxilla O
2007 297 32 M PBL NHL EN maxilla O
2007 298 39 M PBL NHL EN mandible O
2007 299 37 M PBL NHL EN lip O
2007 300 50 M PBL NHL EN gingiva O
2007 301 16 M NLP HL HL N cervical LN EO
2007 302 38 F Atypical BL NHL EN Submandibular area EO
2007 303 74 F DLBCL NHL EN Salivary gland EO
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2007 304 36 M NLP HL HL N cervical LN EO
2007 305 31 F Peripheral T -cell lymphoma (NOS) NHL EN maxilla O
2007 306 32 M NS CHL HL N cervical LN EO
2007 307 34 M Peripheral T -cell lymphoma (NOS) NHL EN palate O
2007 308 66 F FL NHL EN WR O
2006 309 47 M PBL NHL EN maxilla O
2006 310 29 M DLBCL NHL EN palate O
2006 311 34 M PBL NHL EN buccal mucosa O
2006 312 31 M PBL NHL EN maxilla O
2006 313 31 M DLBCL NHL EN maxilla O
2006 314 30 F DLBCL NHL EN gingiva O
2006 315 37 M DLBCL NHL EN gingiva O
2006 316 28 M PBL NHL EN maxilla O
2006 317 50 F DLBCL NHL N max-facial LN EO
2006 318 37 F DLBCL NHL EN Salivary gland EO
2006 319 31 M DLBCL NHL EN gingiva O
2006 320 53 M PBL NHL EN maxilla O
2006 321 28 F DLBCL NHL EN Jaw (NOS) O
2006 322 39 F PBL NHL EN buccal mucosa O
2006 323 42 F PBL NHL EN palate O
2006 324 33 F PBL NHL N max-facial LN EO
2006 325 52 M PBL NHL EN gingiva O
2006 326 54 F PBL NHL EN mandible O
2006 327 32 M PBL NHL EN buccal mucosa O
2006 328 45 F DLBCL NHL EN mandible O
2006 329 57 F Extraosseous plasmacytoma NHL EN nasal cavity EO
2006 330 44 F DLBCL NHL EN palate O
2006 331 29 F MC CHL HL EN palate O
2006 332 55 M Mantle cell lymphoma NHL N cervical LN EO
2006 333 33 M Atypical BL NHL EN buccal mucosa O
2006 334 28 F Atypical BL NHL EN gingiva O
2006 335 59 F Atypical BL NHL N max-facial LN EO
2006 336 26 F Burkitt-like lymphoma NHL EN mandible O
2006 337 42 F Burkitt-like lymphoma NHL EN Submandibular area O
2006 338 54 M FL NHL N cervical LN EO
2006 339 30 F NS CHL HL N cervical LN EO
2006 340 47 M PBL NHL EN gingiva O
2005 341 50 F PBL NHL N cervical LN EO
2005 342 77 F MALT lymphoma NHL EN palate O
2005 343 63 M SLL NHL EN Jaw (NOS) O
2005 344 43 M Peripheral T -cell lymphoma (NOS) NHL N max-facial LN EO
2005 345 65 F Extraosseous plasmacytoma NHL EN nasal cavity EO
2005 346 43 F Plasma cell myeloma NHL EN Paranasal sinuses EO
2005 347 37 M PBL NHL EN maxilla O
2005 348 56 M SLL NHL EN Tongue O
2005 349 31 F DLBCL NHL EN Oral cavity (NOS) O
2005 350 42 F NLP HL HL N cervical LN EO
2005 351 41 F DLBCL NHL EN maxilla O
2005 352 34 F PBL NHL EN buccal mucosa O
2005 353 40 M DLBCL NHL EN buccal mucosa O
2005 354 28 M PBL NHL EN maxilla O
2005 355 39 M PBL NHL EN palate O
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2005 356 53 F PBL NHL EN palate O
2005 357 43 M BL NHL EN maxilla O
2005 358 45 M PBL NHL N cervical LN EO
2005 359 33 F PBL NHL EN palate O
2005 360 82 M FL NHL N cervical LN EO
2005 361 39 M PBL NHL EN maxilla O
2005 362 48 F DLBCL NHL EN maxilla O
2005 363 51 M BL NHL EN mandible O
2005 364 32 F PBL NHL EN maxilla O
2005 365 48 M PBL NHL EN maxilla O
2004 366 34 M PBL NHL EN mandible O
2004 367 64 M Solitary plasmacytoma of bone NHL EN mandible O
2004 368 unknown F DLBCL NHL EN mandible O
2004 369 29 F PBL NHL EN palate O
2004 370 80 M SLL NHL EN maxilla O
2004 371 43 M DLBCL NHL EN Tongue O
2004 372 42 F Peripheral T -cell lymphoma (NOS) NHL EN gingiva O
2004 373 20 F NS CHL HL N max-facial LN EO
2004 374 31 M PBL NHL EN gingiva O
2004 375 54 F FL NHL N max-facial LN EO
2004 376 45 F DLBCL NHL EN Salivary gland EO
2004 377 74 M DLBCL NHL EN maxilla O
2004 378 40 F DLBCL NHL EN palate O
2004 379 31 F Peripheral T -cell lymphoma (NOS) NHL EN Oropharynx O
2004 380 32 M PBL NHL EN palate O
2004 381 23 M PBL NHL EN mandible O
2004 382 59 M DLBCL NHL EN buccal mucosa O
2004 383 68 F FL NHL N cervical LN EO
2004 384 52 F DLBCL NHL EN palate O
2004 385 26 F PBL NHL EN maxilla O
2004 386 44 F B-cell NHL (NOS) NHL EN Floor of mouth O
2004 387 52 M PBL NHL EN buccal mucosa O
2004 388 28 F MC CHL HL N cervical LN EO
2004 389 65 F DLBCL NHL EN Oropharynx O
2004 390 84 F SLL NHL N cervical LN EO
2004 391 31 M T-cell rich B-cell Lymphoma NHL EN Salivary gland EO
2004 392 51 M Plasma cell myeloma NHL EN maxilla O
2004 393 44 F PBL NHL EN palate O
2004 394 30 M Burkitt-like lymphoma NHL N cervical LN EO
2003 395 44 M DLBCL NHL EN Tongue O
2003 396 34 M NLP HL HL N cervical LN EO
2003 397 40 M PBL NHL EN Submandibular area EO
2003 398 62 M DLBCL NHL EN Salivary gland EO
2003 399 21 M NLP HL HL N max-facial LN EO
2003 400 50 M DLBCL NHL EN Submandibular area EO
2003 401 36 M PBL NHL EN buccal mucosa O
2003 402 34 F DLBCL NHL N cervical LN EO
2003 403 34 M PBL NHL EN gingiva O
2003 404 61 F SLL NHL EN Tongue O
2003 405 29 F DLBCL NHL EN gingiva O
2003 406 35 F PBL NHL EN palate O
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2003 407 52 F Peripheral T -cell lymphoma (NOS) NHL N cervical LN EO
2003 408 28 M Acute undifferentiated leukemia NHL EN Paranasal sinuses EO
2003 409 78 F MALT lymphoma NHL EN mandible O
2003 410 20 F PBL NHL EN gingiva O
2003 411 34 F DLBCL NHL EN gingiva O
2003 412 32 F PBL NHL EN maxilla O
2003 413 unknown M NLP HL HL N cervical LN EO
2003 414 32 M PBL NHL EN buccal mucosa O
2003 415 41 M PBL NHL EN palate O
2003 416 61 F MALT lymphoma NHL EN Salivary gland EO
2003 417 47 M PBL NHL EN mandible O
2003 418 39 M PBL NHL EN maxilla O
2003 419 41 M PBL NHL EN Oral cavity (NOS) O
2003 420 43 M NK/T-cell lymphoma NHL EN palate O
2003 421 unknown M BL NHL EN mandible O
2003 422 48 F DLBCL NHL N cervical LN EO
2003 423 34 M PBL NHL EN gingiva O
2003 424 3 M BL NHL EN mandible O
2002 425 37 M NK/T-cell lymphoma NHL EN Paranasal sinuses EO
2002 426 33 F B-cell NHL (NOS) NHL EN mandible O
2002 427 26 M Acute undifferentiated leukemia NHL EN buccal mucosa O
2002 428 32 M PBL NHL EN palate O
2002 429 46 M MALT lymphoma NHL EN palate O
2002 430 27 F PBL NHL EN gingiva O
2002 431 52 M DLBCL NHL N cervical LN EO
2002 432 26 F PBL NHL EN Oral cavity (NOS) O
2002 433 40 M DLBCL NHL N max-facial LN EO
2002 434 unknown F DLBCL NHL N cervical LN EO
2002 435 31 F PBL NHL EN gingiva O
2002 436 50 F PBL NHL EN Oral cavity (NOS) O
2002 437 33 M DLBCL NHL N cervical LN EO
2002 438 44 F PBL NHL EN Tongue O
2002 439 10 M BL NHL EN mandible O
2002 440 71 M DLBCL NHL EN palate O
2002 441 50 F DLBCL NHL N cervical LN EO
2002 442 50 F DLBCL NHL EN Submandibular area O
2002 443 50 M DLBCL NHL EN gingiva O
2001 444 32 M PBL NHL EN Jaw (NOS) O
2001 445 58 F MALT lymphoma NHL EN Salivary gland EO
2001 446 72 F MALT lymphoma NHL EN palate O
2001 447 50 M DLBCL NHL EN maxilla O
2001 448 26 M PBL NHL EN Face EO
2001 449 52 F Extraosseous plasmacytoma NHL EN Retromolar mucosa O
2001 450 10 M BL NHL EN Jaw (NOS) O
2001 451 47 F MC CHL HL N cervical LN EO
2001 452 50 F Solitary plasmacytoma of bone NHL EN maxilla O
2001 453 2 M BL NHL EN mandible O
2001 454 3 Unknown DLBCL NHL EN Salivary gland EO
2001 455 34 M Solitary plasmacytoma of bone NHL EN palate O
2001 456 82 M DLBCL NHL N cervical LN EO
2001 457 31 F DLBCL NHL N cervical LN EO
2001 458 32 F DLBCL NHL EN palate O  
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2001 459 unknown F DLBCL NHL EN gingiva O
2001 460 60 M Anaplastic large cell lymphoma NHL EN buccal mucosa O
2001 461 34 F Burkitt-like lymphoma NHL EN buccal mucosa O
2001 462 38 F PBL NHL EN palate O
2001 463 47 M Anaplastic large cell lymphoma NHL EN gingiva O
2001 464 70 F MALT lymphoma NHL EN Salivary gland EO
2000 465 36 F PBL NHL EN mandible O
2000 466 26 M Plasma cell myeloma NHL EN palate O
2000 467 13 M BL NHL EN maxilla O
2000 468 69 F Solitary plasmacytoma of bone NHL EN mandible O
2000 469 36 F PBL NHL EN Tongue O
2000 470 26 M DLBCL NHL N cervical LN EO
2000 471 62 M DLBCL NHL EN gingiva O
2000 472 73 F Mantle cell lymphoma NHL EN lip O
2000 473 72 F DLBCL NHL N cervical LN EO
2000 474 6 F BL NHL EN Jaw (NOS) O
2000 475 63 F DLBCL NHL EN Posterior nasal space EO
2000 476 34 M DLBCL NHL EN palate O
2000 477 5 F Burkitt-like lymphoma NHL EN Paranasal sinuses EO
1999 478 22 M DLBCL NHL EN Jaw (NOS) O
1999 479 57 M Extraosseous plasmacytoma NHL EN gingiva O
1999 480 40 M DLBCL NHL N max-facial LN EO
1999 481 16 F NK/T-cell lymphoma NHL EN maxilla O
1999 482 32 M PBL NHL EN mandible O
1999 483 28 M DLBCL NHL EN buccal mucosa O
1999 484 85 F SLL NHL N cervical LN EO
1999 485 39 F DLBCL NHL EN mandible O
1998 486 21 F BL NHL EN maxilla O
1998 487 5 F BL NHL EN maxilla O
1997 488 54 M FL NHL N cervical LN EO
1997 489 12 F Solitary plasmacytoma of bone NHL EN palate O
1997 490 42 F NLP HL HL N cervical LN EO
1996 491 58 F MC CHL HL N cervical LN EO
1996 492 69 F T-cell lymphoma (NOS) NHL EN maxilla O
1996 493 28 M BL NHL EN maxilla O
1995 494 25 M DLBCL NHL EN neck EO
1995 495 51 M Plasma cell myeloma NHL EN buccal mucosa O
1994 496 91 M DLBCL NHL EN maxilla O
1994 497 unknown M Anaplastic large cell lymphoma NHL EN gingiva O
1994 498 14 F NLP HL HL N cervical LN EO
1993 499 23 F DLBCL NHL N cervical LN EO
1993 500 44 M MC CHL HL N cervical LN EO
1993 501 12 F Lymphoblastic lymphoma (NOS) NHL EN palate O
1993 502 11 M BL NHL EN mandible O
1993 503 69 F DLBCL NHL EN palate O
1993 504 100 F Solitary plasmacytoma of bone NHL EN maxilla O
  
